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Abstract 
 
 
Introduction  
The Gram positive bacterium Staphylococcus aureus, is part of normal human microbiota 
and colonises approximately one third of all people at any one time.  However, it is also an 
important cause of a variety of infections, which can range from minor to life threatening. A 
relatively recent development has been the rise of antibiotic resistant clones of S. aureus 
in the community, in countries around the world.  These are collectively known as 
community-associated meticillin-resistant S. aureus (CA-MRSA). Within this group, 
particular genotypes and patterns of virulence gene expression have been associated with 
characteristic patterns of infection. There is also evidence that there have been increases 
in a variety of staphylococcal infections since the advent of CA-MRSA, the rise of which 
has also led to reconsideration of appropriate antibiotic treatment options. CA-MRSA was 
recognised early (1980s to 1990s) in Australia and has become an established cause of 
infections. 
 
Studies 
The studies used Australian hospital admissions coding data for staphylococcal associated 
skin infections and information on staphylococcal infection associated admissions in 
children in the state of Queensland and from a Queensland tertiary children’s hospital. The 
data was used to examine the extent, the affected patient groups and timing of the rise of 
CA-MRSA in Australia. Levels of antibody to a staphylococcal toxin (Panton Valentine 
Leukocidin (PVL)) in human sera from persons across the age range, reports on S. aureus 
bloodstream infections in children from around the world and CA-MRSA causing severe 
eye infections and S. aureus causing skin infections at the Queensland children’s hospital 
were also studied. 
 
Outcomes 
Key findings of the studies presented, are that national hospital admissions for 
furunculosis, a skin infection commonly caused by S. aureus (and CA-MRSA clones) more 
than doubled in number per year in the period 1999 to 2014, with particular increases in 
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children and young people. This was at the time when reports of CA-MRSA emerged and 
began to increase in Australia, particularly affecting children and younger adults. 
Additionally, in Queensland children, admission rates for common skin infections rose 
approximately 40% over the period 2000-2011, with infections caused by antibiotic 
resistant bacteria becoming more evident from 2005 onwards and increasing 3 to 4 fold. 
Data from the tertiary children’s hospital showed that antibiotic (meticillin) resistance rose 
to approximately one third of all S. aureus isolates causing common community infections 
(from 2005 onwards), with indigenous children at greater risk. A new finding in Australia, of 
CA-MRSA clones causing serious eye infections was described and placed in context of 
the worldwide early reports of such infections. PVL positive S. aureus was identified as 
causing skin infections in children in a small scale application of newer technology (whole 
genome sequencing) which has become increasingly available for the characterisation of 
bacteria. 
 
Conclusion  
CA-MRSA has led to significant increases in skin infections in Australia over a short period 
of time, with children and young people particularly affected. Treatments for both minor 
and more severe infections have had to be reconsidered to take into account increased 
CA-MRSA as a cause of infection. The rapidity and potential patient impact of the rise in 
CA-MRSA highlights the need for ongoing, timely monitoring of changes in S. aureus 
infection epidemiology, which can guide appropriate treatment. New applications of 
technology such as bacterial whole genome sequencing are likely to enhance the capacity 
for such studies. Identification of methods to better manage and to reduce the burden of 
CA-MRSA infections remains a health priority. 
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Staphylococcus aureus is a bacterium that colonises up to a third of humans at any 
time.  It is successful as both a coloniser and pathogen, causing a range of 
infections, from minor skin infections, to severe invasive infections with significant 
mortality.  As a cause of infections in both the community and within the hospital 
system, treatment and prevention of S. aureus infections has significant health 
system impact and priority (1). 
An important aspect of S. aureus infections in the antibiotic era has been the early 
emergence of antibiotic resistance, limiting treatment options (2). For example, 
shortly after the introduction of penicillin (1940’s), resistance was seen in S. aureus, 
mediated by plasmid encoded narrow spectrum β-lactamases (penicillinases) and 
became present relatively quickly in the majority of S. aureus strains.  After the 
introduction of the staphylococcal penicillinase stable β-lactam, meticillin, resistance 
was also quickly noted (1961;(3)), with the chromosomal genetic element SCCmec 
responsible. The included mecA gene encoded a penicillin binding protein (PBP2) 
whose function was not inhibited by β-lactams then available. Meticillin resistant S. 
aureus (MRSA) clones went on to become well established as causes of 
(particularly) hospital associated (HA-MRSA) infection worldwide,  typically carrying 
SCCmec elements types I-III (4). Present in SCCmec elements are regulatory 
elements and in some (II, III), sites of insertion of resistance genes to other 
antibiotics, leading to the multi-antibiotic resistant phenotypes commonly seen in HA-
MRSA. 
Community Associated MRSA            
A significant development within the last two decades has been the occurrence and 
rise of antibiotic resistant S. aureus clones causing infections in patients in the 
community (CA-MRSA). An early definition used by the United States of America 
(USA) Centers for Disease Control and Prevention (CDC) defined CA-MRSA as 
being isolated from patients without known prior MRSA and without recent 
hospitalisation or other health system contact (such as use of dialysis), or the 
presence of percutaneous catheters (5), with this definition likely to exclude MRSA 
detected in circumstances usually associated with HA-MRSA. 
CA-MRSA strains differ epidemiologically and molecularly from HA-MRSA.  There 
are differences in the mecA structure (SCCmec types IV, V) and in genetic 
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components that may influence pathogenicity. For example, many CA-MRSA strains 
encode Panton-Valentine leukocidin (PVL), a toxin (4) that can be associated with 
severe and necrotising infections. 
Epidemiology of CA-MRSA                 
With Australian descriptions in remote areas of Western Australia in the 1980’s 
among the earliest (6), CA-MRSA clones causing infections in humans have been 
documented worldwide (7). These clones cause serious infections such as fatal 
necrotising pneumonia (8),  osteomyelitis and disseminated infections (9), but the 
majority of infections are of skin and soft tissue (SSTIs) (10).  
In the USA, CA-MRSA was first reported among intravenous drug users (IVDU) in 
the early 1980s (11), with further reports over the next two decades including in 
children (12, 13). A significant report in 1999 was of fatal CA-MRSA infections in 4 
children in Minnesota and North Dakota (14).  Larger scale outbreaks of SSTI by CA-
MRSA clones USA300 and USA400 were then reported in a variety of populations 
such as the homeless and IVDU (15), jail inmates (16) and professional footballers 
(17). Subsequently, CA-MRSA has been reported as the most common identified 
cause (59%) of SSTIs in an emergency department (ED) population (18), with a 
figure of 63% in a hospital and community clinic study from Atlanta, Georgia (19). 
Other populations in whom CA-MRSA was described included urban disadvantaged 
populations, in the military and in indigenous persons in North America and 
Australia. Contact with animals was also a risk for particular sequence types, with 
ST398 associated with livestock contact in Europe (4).  In many reports, children and 
young adults were disproportionally affected by CA-MRSA infections (20, 21). In 
paediatric hospital series, 55% of community onset S aureus infections were caused 
by MRSA (22) in Chicago and New York (23), with proportions as high as 76% in 
North Carolina (24) and Texas (25) hospitals. 
 
CA-MRSA epidemics have been described worldwide with similarities in 
epidemiology, though clones vary with geography (2). Paediatric hospital series 
documenting CA-MRSA as a cause of community associated S. aureus infections 
have also been reported from countries including Canada (5.4% CA-MRSA) (26), 
Brazil (4.9%) (27), Greece (62%) (28) Taiwan (56%) (29) and New Zealand  (NZ; 
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12% in staphylococcal sepsis requiring ICU admission, 6% in a bacteraemia series 
and 20% in OAI and SSTI series) (30-32). 
 
Increases in particular infections often caused by S aureus have also been noted, for 
example osteomyelitis (33, 34) increasing from 6.95 to 19.4 cases per 100,000 in a 
Texan region (34) and in cases of MRSA pneumonia / empyema (35). All-cause 
empyema hospitalisations increased from 3.5 to 7.0 per 100,000 children less than 2 
years of age (1996-1998 to 2005-2007 respectively) with over half of this increase 
due to staphylococcal infections (sensitivities not described) in a 2010 report using a 
US nationwide inpatient sample (36).  
  
MRSA clones originally described as ‘community-acquired’ have also been noted to 
be transmissible within the hospital environment and to cause nosocomial infections.  
These include infections and colonisation in neonates (37) and nosocomial 
bacteraemia (38). 
Molecular Epidemiology of CA-MRSA                  
The rise in CA-MRSA reports from a number of countries (7) have involved different 
S. aureus clones. The population structure of S. aureus is described as ‘clonal’ (39). 
Clones are genetically similar, with the implication of descent from a same recent 
ancestor (40).  Core genomes of S. aureus clones are similar and genetic 
recombination events (larger scale genetic exchange) are relatively uncommon. 
Such clones are defined by sequence type (ST), determined by Multi Locus 
Sequence Typing (MLST) based on (having identical) gene sequences at multiple 
conserved regions of the genome. Clones are also frequently described by the 
SCCmec type and presence of PVL. Additionally, clones may also have names 
derived from geographic region of association / first description and pulse field gel 
electrophoresis (PFGE) characteristics.  Examples include USA300 (ST8-MRSA-IV 
PVL+) (4) and the ‘Queensland’ clone (ST93-MRSA-IV PLV+) (41). 
It has been suggested that CA-MRSA clones arose by the acquisition of SCCmec 
elements by community meticillin sensitive S. aureus (MSSA) clones (42). In the 
USA, early reports involved USA400 (14) which was a ST1-MRSA-IV PVL+, but the 
subsequent rapid rise in CA-MRSA infections related to USA300 (4). These clones 
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(USA300, USA400) (43, 44) were also defined by PFGE characteristics. Additional 
S. aureus typing methods, which relate to sequences at various parts of the genome, 
include use of staphylococcal protein A (spa) and accessory gene 
regulator (agr) typing, deoxyribonucleic acid (DNA) microarrays, analysis of the mec 
associated dru region and PVL phage typing among others (42). More recently, 
whole genome sequencing (WGS) methods have been applied in the molecular 
analysis of MRSA isolates (45, 46). Typing information, as per many of the methods 
mentioned above, can also be determined from analysis of the sequences from the 
whole bacterial genome. 
CA-MRSA in Australia 
In Australia, following early descriptions in indigenous persons in remote areas of 
Western Australia and in the Northern Territory (‘WA-MRSA’ clones) (6), PVL + CA-
MRSA infections were noted in East coast states in the late 1990’s (initially in 
persons of Polynesian ethnicity) and shown to be due to ST30-MRSA-IV, the South-
West Pacific clone previously reported in NZ (6). Subsequently, the new 
‘Queensland’ clone ST93-MRSA-IV was described in 2003 (41), and has gone on to 
become the predominant CA-MRSA clone in Australia, making up 41% of CA-MRSA 
in a national survey of community onset S. aureus infections (42, 47, 48). While 
several ST93-MRSA strains have been noted in Australia, the majority were of the 
predominant strain ST93-IVa [2B]-t202-dt10 (42, 49). 
 
Recent (2012) data indicate CA-MRSA as the cause of 12.5% of community onset S 
aureus infections in a national laboratory based study, with significant regional 
variations in the proportion of MRSA isolates that were community-associated and in 
the distribution of the multiple CA-MRSA genotypes that are present in Australia 
(47). In Queensland, a >200% increase in outpatient MRSA patient sample isolations 
between 2000 and 2006 has been reported (50) and in a skin abscess case series 
from western NSW, 30% of infections were caused by CA-MRSA (51). In the 
Northern Territory, the proportion of meticillin resistance in S. aureus isolates from 
community clinics serving indigenous people rose from 7% to 24% between 1993 
and 2012 (52). In Western Australia (MRSA infections notifiable), an MRSA 
notification rate of 179/100,000 was seen in 2006 of which 144/100,000 was CA-
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MRSA by genotype (6). The highest proportion of PVL positive MRSA clones were 
seen from patients between 10-30 years of age in the 2006 national survey (48). 
CA-MRSA Infections in Australian Children        
Literature on CA-MRSA in Australia relating specifically to children includes reports 
of cases of severe infections including sepsis, osteomyelitis, necrotizing pneumonia 
and multifocal infection (9, 53). Broader epidemiological descriptions include a 
paediatric hospital series of S aureus infections in which  9% of isolates had 
antibiograms consistent with CA-MRSA (2001-2002 isolates, Sydney)  (54) and a 
community onset osteoarticular infection (OAI) series (cases from 1998-2002, 
Sydney) with 9% of microbiologically diagnosed osteomyelitis cases and 6% of 
septic arthritis cases due to MRSA (55).  By 2008, 20% of community associated S. 
aureus infections treated at a tertiary paediatric hospital in western Sydney were 
MRSA (56). 
CA-MRSA Virulence Factors                  
CA-MRSA clones are a consistent cause of skin and soft tissue infections. SSTIs 
have been strongly associated with PVL positive S. aureus clones (both MRSA and 
MSSA) (10) and much attention and debate has surrounded the role of PVL in 
pathogenesis (4). 
PVL is a secreted bi-component pore-forming leukotoxin encoded by genes on 
bacteriophages. It was described in the 19th century and associated with SSTI early 
in the 20th century (4, 57). It has cytotoxic actions on human neutrophils (58). A role 
in enhancing skin infections has been reported in rabbit models using isogenic 
strains with / without PVL in some reports (59) but not in others (60). Similarly, 
enhancement of osteomyelitis severity has been shown (61). However, reports from 
mice models concluded that PVL is not a virulence determinant (62). Other reports 
have reported on the importance of other staphylococcal toxins / virulence 
determinants such as phenol soluble modulin alpha and alpha-haemolysin (Hla) 
(cytolytic toxins) (60, 63, 64). ST93, the Queensland clone is known to encode 
phenol soluble modulin alpha and alpha-haemolysin as well as PVL (49) and is 
virulent in animal infection models. The function of core genome regulators such as 
agr in CA-MRSA clones may contribute to virulence as they lead to high expression 
of multiple virulence factors and toxins (65). 
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Conflicting results on PVL effects from different animal models may reflect in part  
differences in action in different species (58), with neutrophil cytotoxicity seen in 
human and rabbit cells but not in mouse or simian cell lines.  Its role in the 
pathogenicity of CA-MRSA has been debated (4), but its presence in multiple CA-
MRSA clones worldwide (7),  association with SSTI and of PVL +  S. aureus with 
infection in younger persons (47, 66) has been widely noted. 
CA-MRSA Infections & Treatment           
Pyogenic SSTI, in particular abscesses or boils make up the majority of CA-MRSA 
infections (10, 66).  Incision and drainage is often highly effective without the addition 
of active antibiotic agents (67, 68) and is recommended as the primary treatment 
(69), with antibiotic therapy used for complicated cases. Available treatment options 
may be influenced by the antibiotic susceptibility patterns of CA-MRSA clones, but 
clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are among the 
recommended oral agents.  Studies have supported the effectiveness of these 
agents in SSTI in both adults (70, 71) and children (71-73). Multiple recurrences of 
SSTI can occur and prove burdensome for affected individuals as well as the health 
system.  
Severe invasive infections are less common but include severe SSTI (including 
necrotizing fasciitis (74)), osteoarticular infections, necrotising pneumonia, 
multisystem sepsis (9), endocarditis (75) and cavernous sinus thrombosis and 
meningitis (76).  Appropriate treatment may include surgery and supportive care.  
Recommended antimicrobials may include vancomycin, clindamycin, daptomycin 
and linezolid (69). Sub-inhibitory concentrations of certain antibiotics may have a 
toxin inducing effect in CA-MRSA (77, 78), with this effect inhibited in vitro for 
example by clindamycin and linezolid. Treatment strategies with anti-toxin activity, 
such as choice of antibiotic and intravenous immunoglobulin (IVIG) have been 
suggested (79). These are not however, routinely recommended, for example not in 
the Infectious Diseases Society of America (IDSA) MRSA treatment guidelines  (69). 
However, recommendations to use antibiotics with anti-toxin effect and IVIG in 
selected cases where severe PVL +  S. aureus  infection was suspected were made 
by the United Kingdom (UK) Health Protection Agency in 2008 (80) and as expert 
opinion by researchers in the field (81). Reports on the use of such strategies have 
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been noted in case reports (82) and series (83) including from Australia (84). These 
adjunctive strategies have found application in Australia – with for example use of 
anti-toxin antibiotics being incorporated into the management of severe S. aureus  
infections at a Brisbane paediatric hospital (84). 
Antibiotic resistance in bacteria may lead to antibiotic choices that are limited, 
potentially less effective and/or have cost and side effect implications. Vancomycin 
may be slower to achieve bacteriocidal activity than anti-staphylococcal penicillins in 
certain in vitro conditions (85). This may have a role in observed MRSA vs. MSSA 
bacteraemia mortality differences, however, reasons for mortality differences are 
much debated and multiple factors may be involved (86). Linezolid (the first 
oxazolidinone) has in some studies had higher cure rates than vancomycin (87) and 
is recommended as a treatment option for MRSA pneumonia (69).  However, it has 
high cost and side effects include myelosuppression and peripheral neuropathy with 
prolonged use (87). Other available treatments include daptomycin (not suitable for 
treatment of pneumonia), telavancin, oritavancin and dalbavancin 
(lipoglycopeptides), ceftaroline, an anti-MRSA cephalosporin able to bind (and 
inhibit) MRSA PBP2 and tedizolid (another oxazolidinone) (87-91). Drugs under 
development include other oxazolidinones (radezolid), lipoglycopeptides, 
fluroquinolones (87) and pleuromutilins, bacterial proteins synthesis inhibitors with 
Gram positive activity including against MRSA (92). 
CA-MRSA Prevention           
Attempts at preventing CA-MRSA infections have been made, for example, in 
persons experiencing recurrent SSTI, contacts of persons with CA-MRSA infection, 
in communities with persons in close contact experiencing infections  and to prevent 
introduction of virulent strains to an area where they have not been previously 
present or common (93).  For the latter, a mechanism to detect introduction of such 
strains and act on such information is required (for example through the activity of a 
public health service).  
Fomites and direct contact with other persons is thought to be important in the 
transmission of CA-MRSA (94). Prevention measures include management of 
infections, hygiene measures to prevent transmission between persons or through 
fomites (such as hand hygiene and environmental cleaning) and decolonisation of 
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individuals with antibiotics and antibacterial washes (69). A recent article (95) 
collated eight reports (96-103) which included accounts of prevention measures, with 
the majority being successful, for example in terminating outbreaks of CA-MRSA 
SSTI in sporting teams (103) and in a Swiss community (99). However, not all 
attempts at prevention are reported as being effective (104, 105). 
CA-MRSA and S. aureus Infection Epidemiology               
The rise of CA-MRSA has been shown to have increased overall S. aureus 
infections and health care burden on a population level, particularly in a number of 
US reports. For example, with increased ambulatory care and ED visits,;up to a 50% 
increase in one study  (106, 107) and hospitalisations for SSTIs (108).  Increased 
costs to a health system from SSTIs have been documented (109) and yearly costs 
to society modelled in the billions of dollars (110). The majority of infections may be 
managed in the community (only 23% hospitalised in one investigation (20)), and 
overall infection rates across a variety of settings difficult to determine. 
 
Recent increases in staphylococcal infections have also been usefully studied using 
large hospitalisation data sets, making use of International Classification of Diseases 
(ICD) coding of each hospital admission.  Klein et al (108) used a US national 
hospital admissions sample (ICD-9 coding) to estimate a 62% increase in S. aureus 
hospitalisations between 1999 and 2005 with MRSA related hospitalisations doubling 
in that time. Gerber et al (111) using ICD-9 coded data from a number of paediatric 
hospitals US-wide, showed a significant increase in hospitalisations due to MRSA 
infections, from 6.7 to 21.1 per 1000 admissions between 2002 and 2007.  
Admissions for MSSA infections remained stable (14.1 to 14.7/1000); hence there 
were more MRSA than MSSA infection admission episodes at the end of the time 
period. The result was a >70% increase in the overall S. aureus infection admission 
rate (20.8 to 35.8/1000) driven by MRSA infections.  The median age of these 
admitted patients was 3.1 years, less than one third had chronic medical conditions 
and of the identified infections, SSTIs made up 61%; overall mortality was 1%. In NZ, 
Williamson et al (112), showed an increase in staphylococcal SSTI hospitalisations 
(but not for sepsis or pneumonia) between 2000-2011 using national ICD-10 coded 
discharge data.  In England, UK, Saxena et al (113) showed a 49% increase in SSTI 
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and osteoarticular hospitalisations (commonly caused by S. aureus; ICD-10 data) in 
children between 1997 and 2006. 
 
Use of recorded, coded hospitalisation data allows for analysis of larger (even 
national) numbers of episodes over time, allowing for assessment of changes in 
frequency of particular hospitalisation causes.  Available information includes the 
principal diagnosis and potentially information on microbial cause of an infection 
including antimicrobial resistant bacteria (114). Data are dependent on the accuracy 
and completeness of coding and may be influenced by changes in coding definitions 
or practice over time and additionally there are limits to the information that can be 
inferred from coding.  
In the context of the rise of CA-MRSA as a cause of infection in Australia, this study 
sought to gain information on the impact on S. aureus infection epidemiology of 
these developments.  A particular emphasis was on examining these questions in 
data from children in the state of Queensland. 
Hypothesis               
CA-MRSA has led to increases in staphylococcal infections in Australia and is an 
increased cause of staphylococcal infections in Australian children. 
Aim                                                              
The studies seek to determine how much change there has been in S. aureus 
infections in the era of CA-MRSA, over what period of time changes occurred, who is 
affected by these infections, where they have occurred and what can be understood 
from the nature of these changes. 
Objectives                                   
To collect and analyse data on national hospital admissions for cutaneous 
abscesses and for common staphylococcal associated infection admissions in 
Queensland children and from a Queensland tertiary children’s hospital and to 
examine CA-MRSA as a cause of serious eye infections and S. aureus as a cause of 
SSTI at that hospital. 
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Components                
Chapter 2, Part A documents recent significant changes in Australia wide hospital 
admissions for cutaneous abscesses – an infection particularly associated with S. 
aureus, CA-MRSA and PVL positive clones. Part B reports on antibodies to the 
putative S. aureus virulence factor, PVL, across different ages groups and in 
relationship to the age groups experiencing such PVL+ infections. 
Chapter 3 examines hospitalisation data for common S. aureus associated infections 
in Queensland children for recent changes in the occurrence of these infections in 
context of the rise of CA-MRSA. 
Chapter 4, Part A analyses common S. aureus infections at a Queensland tertiary 
children’s hospital over a recent decade and provides direct evidence (from 
microbiology laboratory data) for the role and rise of CA-MRSA as a cause of S. 
aureus infections. Part B presents genotype data from WGS analysis on a collection 
of S. aureus isolates causing community onset SSTIs at a Queensland tertiary 
children’s hospital. 
Chapter 5, Part A presents a series of severe CA-MRSA ocular infections – the first 
of its kind in Australia – and places these in context of reports in the literature at the 
time. Part B, a literature review of reports on S. aureus bacteraemia in children in a 
number of countries, provides information on what is known about this infection and 
what information is available on recent trends, including in meticillin resistance. 
Chapter 6 is a discussion of the component studies collectively. 
 
 
 
 
 
 
12 
 
 
Chapter 2 
National changes in S. aureus associated infections 
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Part A 
Increases in Australian cutaneous abscess hospitalisations: 1999-2014 
 
Abstract 
 
Purpose 
Staphylococcus aureus is the most common cause of skin and soft tissue infections. 
Such infections have increased in both community and hospital treatment settings in 
several countries recently and at a time when community-associated meticillin-
resistant S. aureus strains have emerged globally. We examined changes in national 
hospitalisation data for treatment of cutaneous abscesses between 1999 and 2014, 
a period when increased numbers of CA-MRSA infections were being reported in 
Australia.                              
 
Methods 
National hospital discharge data for cutaneous abscess treatment between 1999 and 
2014 published by the Australian Institute for Health and Welfare were examined.  
Hospital admission numbers were collated and age-specific admission rates 
calculated and examined for changes over time.   
 
Results 
Yearly admissions for treatment of cutaneous abscesses more than doubled from 
8,849 (1999-2000) to 20,189 (2013-2014). The crude annual hospitalisation rate per 
100,000 population was 46 in 1999-2000 and 84 in 2013-2014. However, increases 
in admission rates were limited to the 5-to-69 year age range. Incidence rate ratios 
(IRR) for final versus baseline year admission rates for these age groups were from 
1.37 (95% confidence interval (CI) 1.23-1.51) for those aged 5-9 years to 2.50 (95% 
CI 2.76-3.05) for those 50-54 years of age; p <0.001.                                    
 
Conclusions 
Increases in hospitalisation for cutaneous abscess treatment have occurred in 
Australia during the last decade. Research into the underlying causes and 
prevention of these infections is a public health priority.   
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Introduction 
Skin and soft tissue infections and in particular localised purulent lesions such as 
cutaneous abscesses, furuncles and carbuncles are most commonly caused by 
Staphylococcus aureus (115, 116). Over the past decade, increases in presentations 
with SSTI have been reported. In the US alone, ambulatory care visits for SSTIs 
increased by 50% between 1997 and 2005 (107). These changes in incident cases 
occurred at the same time CA-MRSA clones emerged globally as important causes 
of SSTIs in all age groups (7, 18, 48). 
While CA-MRSA infections have also been recognised increasingly in Australia over 
the past decade (6, 48), whether this change in S. aureus epidemiology has been 
accompanied by an increased burden in SSTIs is unknown. We therefore examined 
national hospital discharge data for cutaneous abscesses during the period 1999-
2014. A version of this analysis using 1999-2008 data, available at the time has been 
published (117).    
 
Methods 
The Australian Institute of Health and Welfare (AIHW) National Hospital Morbidity 
Database is an electronic collection of de-identified records of hospital care, which 
includes all public and private hospitals in Australia. Hospital admissions data are 
presented as number of separations per July to June financial year, for principal 
diagnoses categorised by International Classification of Diseases 10th edition 
Australian Modification (ICD-10AM) codes. Available data variables include age 
group (in 5 year groupings) and information on total and average admission days.   
Data on hospital discharges with a principal diagnosis of cutaneous abscess 
categorised by the ICD-10AM code L02 (cutaneous abscess, furuncle and 
carbuncle) were obtained from national hospital episode data published by AIHW 
(118) for consecutive years between 1999-2000 and  2013-2014 inclusive.  Total 
hospitalisation numbers, hospitalisations by age group, average length of stay 
(ALOS) and total patient (hospital) days for this diagnosis were recorded.  
Age-specific rates for admissions (in 5-year population age bands) were calculated 
using the mean of the June 30th  population estimates at either end of the respective 
financial year as the denominator (Australian Bureau of Statistics (ABS) (119)). 
Trend analysis for hospitalisation rates was performed by regression using the 
negative binomial distribution, as initial analysis suggested the data were over-
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dispersed with regard to the Poisson distribution (120).  Statistical analysis was 
performed using IBM SPSS Statistics 23 (2015; Chicago, IL.).  
Data on costs of inpatient treatment were obtained from the Australian Independent 
Hospital Pricing Authority cost weights for Australian Refined Diagnosis Related 
Groups (AR-DRG) 2012-2013 (121). As this study used published, publically 
available hospitalisation data summaries, not identifiable at the individual level, no 
ethics review was deemed necessary. 
 
Results 
Total cutaneous abscess hospital episodes rose from 8,849 (July 1999 - June 2000) 
to 20,189 (July 2013 - June 2014), a 128% increase in hospitalisations.  The crude 
annual hospitalisation rate was 46 per 100,000 in 1999-2000 and 84 per 100,000 in 
2013-2014. Total patient-hospital days increased 92% (33,867 days (1999-2000) to 
65,171 (2013-2014)), while ALOS slightly decreased (3.8 days and 3.2 days). 
Hospitalisation rates for cutaneous abscesses varied across the age spectrum with 
highest rates in the first year of life before declining sharply throughout childhood, 
only to increase in adolescence and adulthood before decreasing again later in life 
[Figure 1]. Highest rates (>100 per 100,000) were seen in infants and those 15-49 
years old (2013-2014). During the period surveyed, hospitalisation rates rose 
significantly for groups aged between 5-to-69 years (by incidence rate ratio (IRR), 
comparing the final (2013-2014) with the baseline year (1999-2000) rate for each 
age group, p <0.001).  Rates remained unchanged in those aged 69 years and over. 
The estimated average total cost weight (2012-2013) for a cutaneous abscess 
hospitalisation (ALOS 3 days) was AUD$4,000 for the AR-DRG code J64B ‘Cellulitis’ 
that includes the ICD-10AM codes for cutaneous abscesses.  Hence the estimated 
total cost for cutaneous abscess hospitalisations in Australia for 2013-2014 was 
approximately AUD$81 million. The approximately 11,000 additional annual 
hospitalisations recorded by the end of the study period contributed AUD$44 million 
to this total. 
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FIGURE 1: 
Australian abscess hospitalisations (per 100,000 per year) by age group and year. 
Significant increases in rate (2013-2014 vs. 1999-2000) seen in age groups* 5-69 
years; p<0.001. 
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Discussion 
During the time period studied, there has been an over 100% increase in yearly 
hospitalisations for treatment of cutaneous abscesses in Australian hospitals.  
Moreover, as a US nationwide emergency department survey reported, only 15% of 
patients with cutaneous abscesses required admission to hospital (18) and it is likely 
that there have also been substantially increased numbers of patients with 
cutaneous abscesses presenting for treatment to Australian emergency departments 
and primary health care facilities. Such an increase in presentations for treatment 
has important implications for health care costs beyond the additional AUD $40 
million per annum in hospitalisation costs estimated in this study. Indeed, by relying 
upon ICD coding we may have also under-estimated the true hospital-associated 
costs as not all patients are likely to have been captured by discharge coding 
methodologies (122).                                                                                           
 
Coding relies on the retrospective analysis of original health records that may not 
always be accurate or complete. It has been noted that SSTIs are sometimes 
assigned to the status of additional rather than principal diagnoses due to error or 
coding strategy (122) leading to under counting of episodes. However, comparison 
of data from different years remain possible; with efforts being made to maintain the 
quality of coded data collection over time (123).  Nevertheless, using coding to 
define disease may yield different results from using clinical definitions and other 
information on disease (122, 123). However, routinely collected hospitalisation data 
are widely used in health care studies (123) and provide population level, 
comparable data for the study of trends in infection. 
 
As the AIHW data were only available as counts of hospital episodes and no 
geographic or patient ethnicity information or information on repeat admissions was 
available, these factors were not able to be explored.  As the data were not linked 
with microbiology results, we were unable to directly identify the bacterial pathogens 
associated with the increased abscess hospitalisations.   However, it is accepted that 
S. aureus is the commonest cause of such SSTIs (115, 116) and our study was 
conducted against a background of case series and laboratory reports of significant 
increases in CA-MRSA infections in Australia (50, 51). A 2006 nationwide study of 
community onset S. aureus infections observed that 16% of S. aureus isolates 
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cultured from skin and soft tissue specimens were meticillin resistant (48).This figure 
was 17.9% in the subsequent 2012 survey (47) which noted that the mean age of 
patients with PVL + CA-MRSA was 31.7 years – consistent with age groups seeing 
large rises in abscess hospitalisation rates. Other possible explanations for our 
observations, such as increased susceptibility to cutaneous abscesses among 
particular age groups (over the time period of data), increases in infections by 
bacteria other than S. aureus, changes in hospital admission or coding practices for 
abscess treatment, or global community changes in hygienic behaviour altering 
transmission dynamics seem less likely. During the period studied, the number of 
‘all-cause’ hospitalisations  (by coded separations) rose 64% compared with 128% 
for skin abscesses and the ‘all-cause’ ALOS fell from 3.8 to 2.9 days (118). These 
data suggest disproportionate increases in cutaneous abscess hospital admissions. 
 
Interestingly, the increases in hospitalisation rates for cutaneous abscesses are most 
striking in adolescents and younger adults, without comparable increases in the 
youngest children and oldest adults. As noted in the recent survey of community 
onset S. aureus infections, it was in a younger age group that PVL + CA-MRSA 
infections were mostly seen (47).     Similar patterns of age distribution (i.e. older 
children and young adults particularly affected) have been reported in accounts of S. 
aureus infections in both Australia and NZ (48, 124-126). Possible explanations for 
this apparent age variation in infection risk include increased risk in young adults 
from poor hygiene, sharing fomites and contact with other colonised or infected 
persons (127) or reduced infections in older persons due to acquired immunity. 
Stable, high (compared to other age groups) hospitalisation rates were seen in 
infants and children aged <1 year and 1-4 years of age. This may be because of 
higher rates of infection in young children resulting from an immature immune 
system and/or a lower threshold for hospital admission in this age group.  Higher 
hospitalisation rates for SSTIs in children ≤4 years compared with 5-14 year olds 
have been reported previously, as have lower admission rates for abscesses in older 
adults compared to younger adults (128). The lack of increase in hospitalisation 
rates in the youngest children is in contrast to rates in the older children and younger 
adult age groups. If ‘social contact’ as noted above (127) is important in young 
adults, different patterns of interaction in the youngest children may play a role. 
Routine childhood varicella immunisation commenced in 2005 in Australia and 
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varicella infection associated hospitalisations have decreased since, particularly in 
children under 6 years of age (129).  SSTIs are the most common complication of 
varicella in children (130) and in Canadian data,  varicella SSTI hospitalisations 
dropped particularly in younger children (who had higher baseline rates) following 
implementation of the vaccine program (131).  Hence it is possible that varicella 
vaccination could have attenuated possible increases in SSTI admission numbers in 
this age group. Information on the microbiology of pathogens causing SSTI in the 
various age groups – not available in this study – would assist in further assessing 
these hypotheses. 
 
Our results are also consistent with studies from the US, where community hospital 
discharge data for SSTIs increased by 29% between 2000 and 2004 (132). Another 
US study utilising national hospital discharge data noted a 62% increase in ‘all 
cause’ S. aureus-related hospitalisations between 1999 and 2005 (108).  The 
authors observed that increases in hospitalisations were most marked for cutaneous 
abscesses and cellulitis, with MRSA-related hospitalisations doubling during the 
same period (108). Recent increases in S. aureus associated hospitalisations, 
including SSTIs, have also been documented in the United Kingdom (113, 128). Of 
note is a NZ study of staphylococcal infections (2000-2011) using ICD-10 coded 
national hospital admissions data (112) which found no change in staphylococcal 
pneumonia or sepsis, but found increases in staphylococcal SSTI over that time 
frame. 
 
In summary, in analysis of coded data on all hospitalisations for cutaneous 
abscesses nationwide between 1999 and 2014, admissions had more than doubled 
yearly in Australia. Admission rates per population had increased in children, 
adolescents and younger adults but not in the oldest adults. The cause for these 
increased hospital admissions remain speculative, but have occurred against a 
background of the rapid emergence of CA-MRSA, which with other PVL+ S. aureus 
are closely associated with abscesses and occurrence in younger persons. Our 
study is limited, however, by the lack of linked laboratory diagnostic data for the 
increased hospitalisations noted and more direct evidence to associate CA-MRSA 
with the increases would still be relevant. The increased costs of SSTIs to the 
healthcare system, as well as the morbidity experienced by patients are of concern. 
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Further research to confirm the reasons for these increases in cutaneous abscesses 
is required, as well as identifying effective measures to reduce such infections 
occurring in the future 
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Chapter 2 
 
Part B 
 
Serum levels of antibodies to Panton-Valentine Leukocidin in a sub-
tropical Australian population 
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Introduction 
Recent rapid increases in infection by epidemic clones of CA-MRSA have occurred 
in a number of regions worldwide (4) and have been responsible for population level 
increases in S. aureus infections. Carriage of genes coding for PVL, a phage-related 
bicomponent extracellular toxin is common in CA-MRSA and is associated especially 
with SSTI  (10) and invasive pyogenic infections. Susceptibility to infection with PVL+ 
S. aureus appears maximal in younger age-groups and decreases with advancing 
age (66, 124). PVL+ CA-MRSA and MSSA are common in sub-tropical Queensland 
(124, 126) and PVL antibody levels are known to rise following infections with PVL+ 
S. aureus strains (133-135). The close linkage of PVL with epidemic CA-MRSA, 
SSTIs and infection in younger persons had triggered interest in the importance of 
this virulence factor in the pathogenesis of and susceptibility to these infections (4). 
There is however, limited information available on PVL antibody levels in humans 
and no prior systematic data on levels in the Australian population. Commercial 
assays are not available and studies have been performed using in-house 
immunoassay methods using recombinant antigen to detect antibody (133-136). This 
study sought to measure PVL antibody levels across the age range in persons from 
Brisbane, Queensland. It was hypothesised that PVL antibodies should be present 
and measurable in a Queensland population, that age-related differences in antibody 
levels should be ascertainable and that these differences may relate to age-related 
differences in occurrence or propensity to infection with PVL+ S. aureus. 
 
Method 
Stored, frozen (-20°C) serum samples, previously used for routine clinical pathology 
testing and scheduled for discard, were obtained from a large Brisbane state 
government pathology provider (2011). Samples were chosen with the aim of 
studying changes in antibody levels across the age range, taking into account 
previously available relevant data (133, 135) and to achieve a minimum number 
within age categories (from sample size calculations to allow determination of 
difference in antibody levels, using available data on variation in levels of PVL 
antibody across age groups (133, 137)) and consecutively from available stored 
specimens. The study was approved by the Queensland Children’s Health Services 
Ethics Committee and the Royal Brisbane and Women’s Hospital Institutional 
Review Board. 
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Samples from patients aged from 0 to >70 years were tested using an enzyme linked 
immune-sorbent assay (ELISA) method (136) to determine the prevalence and level 
of antibodies to PVL across the age range, with view to examine differences 
between children, adolescents, young and older adults. Micro-titre plates were 
coated with 100 ul of 5 ug/ml recombinant LukS-PV protein and stored at room 
temperature overnight. Plates were then washed before and after incubation with a 
blocking solution. Sample sera  were  diluted  to  1/1000  (and  1/10,000  if  
required)  and  tested   using  peroxidase  conjugated  rabbit  anti-human  polyvalent  
IgG  reacted  with  tetramethylbenzidine  (TMB)  and quenched  with  H2SO4. Optical 
density was read at 450nm using a microplate reader.  
 
Results were recorded in arbitrary units per litre (AU/L).  The measure was derived 
from testing a commercial intravenous immunoglobulin preparation (Tégéline; 
Laboratoire Français du Fractionnement et des Biotechnologies, Courtaboeuf, 
France) with each run and assigning the result a value of 1,000 AU/L.  The test 
method, recombinant protein and commercial IVIG were kindly provided by 
collaborators at the University of Lyon, France (136). Data  were analysed  using  
SPSS 23 and  results  in  the  different  age  groups  were  compared  using  
the Kruskal  Wallis  test followed by post-hoc pair-wise comparisons. Data were 
presented as range and interquartile range of PVL antibody levels in age groups, 
with GraphPad Prism 7 (GraphPad Software San Diego, USA) used for presentation 
of data. 
 
Results 
Results for 329 serum samples were obtained. Measured levels varied from <100 
AU/L to >10,000 AU. Median levels generally increased with age, with adolescents 
and young adults having higher levels than in younger children; and the older adults 
having the highest levels. Median PVL levels were different by age group (p<0.001). 
In significant (p <0.05) pair-wise comparisons, median PVL antibody levels in <1 
year olds differed (lower levels) from all age groups > 4 years of age and levels in 
≥70 year olds were higher than in 0-9 and 30-50 year olds. See Table 1 and Figure 2 
– log scale box and whisker plot with minimum and maximum values of antibody 
levels by age group. 
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FIGURE 2:  PVL Antibody Levels (AU/L) by Age Group 
Log scale box and whisker plot with minimum and maximum values of antibody 
levels by age group. PVL values vary by age group (p <0.0001).  
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TABLE 1: PVL Antibody Levels (AU/L) by Age Group 
Age Group (years) <1 1-4 5-9 10-19 20-29 30-39 40-49 50-59 60-69 70+ 
Number of values 30 31 32 32 32 38 32 32 32 38 
           
           
Interquartile Range: 225 576 443 883 775 468 949 2367 1407 1994 
           
Range:           
Minimum 27 88 50 145 69 37 53 307 177 42 
Maximum 1375 5392 4204 15055 7861 12360 2992 11530 11391 8770 
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Discussion 
These  results  confirm  that  antibodies  to PVL, which increase following PVL + S. aureus 
infection (133, 134), are  common  in  persons from sub tropical Queensland,  suggesting  
that  exposure  is common.  This  is  in  keeping  with  the significant prevalence  of  PVL+  
CA-MRSA  and  MSSA  in  this  region (126).  Furthermore, antibody levels generally 
increased with age.  Lowest levels were seen in infants, as a previous report in infants 3-
11 months of age found  (135) and these are consistent with a fall in level of transplacental 
maternally derived antibodies in the absence of infections.  A rise in antibody levels is 
seen in adolescent and younger adult groups and these are the age ranges with higher 
cutaneous abscess hospital admission rates in the Australian population (see first part of 
this chapter). This appears to reflect the occurrence of PVL+ infections. A previous study 
found moderate (and increasing) PVL antibody levels in children having initial PVL+ MRSA 
infections, with higher levels (without much further increase) in those with infection who 
had had prior MRSA infection or SSTI (135). This may be relevant to the levels seen in 
older children to middle aged adults where no clear increase or difference between groups 
within these age ranges was shown in the data.  Increased levels in older children 
(compared with younger children) and in older adults has also been described in a study in 
France (133).  
 
High PVL antibody levels were seen in older adults, an age group where PVL+ infections 
are known to be less common, hence these PVL antibody levels presumably reflect past 
infections, and imply longevity of PVL antibodies (in the absence of recent infections). 
However, longitudinal data is not available to clarify this.  PVL + S. aureus infections are 
known to have occurred in Australia in previous decades; phage type 80/81 S. aureus 
became pandemic in the 1950s and were a cause of SSTI and other infections especially 
in children and young adults at the time (138).  
 
The samples tested were sera for discard by a pathology service from a cohort tested in a 
hospital system (a hospital cohort), so applicability of the results to the community 
population more generally should be considered with caution. There was also no 
information on the presence or absence of recent staphylococcal infection associated with 
the samples and hence there is no direct evidence of recent PVL + S. aureus infections 
causing increases in antibody levels. 
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A feature of the data is the high antibody levels in older adults where PVL+ infections are 
not as frequent (66). Whether these increased PVL antibody levels reflect past infection 
only or are protective and therefore contribute to the lower prevalence of PVL+ S. aureus 
in older age groups is uncertain. Prior results on the role of PVL antibodies in protection 
from PVL+ S. aureus infections are limited and conflicting, possibly because of differences 
in site of infection (135, 139) .  A protective effect on mortality from PVL associated 
necrotizing pneumonia has been suggested in those with a history of PVL associated 
infections (139).  However,  another study in children suggested no protection from PVL 
antibody to SSTI  recurrence (135). A mouse study has suggested the PVL vaccination 
could be protective against lung and skin disease (140). However, a correlate of protection 
against S. aureus infections is not clearly established, and recent vaccine studies have 
investigated other S. aureus antigens – e.g. the multi-antigen 4C-Staph vaccine (141). 
 
This study demonstrated that the presence of PVL antibodies in sera in persons from 
Brisbane, Queensland is common.  PVL antibody levels were higher (than in young 
children) in the adolescent and young adult age ranges where PVL + S. aureus are known 
to be common and consistent with prior findings of PVL+ infections leading to production 
of a neutralising antibody response but without particular evidence of a protective effect 
against SSTI in this age group (133, 135).   High levels of antibody were seen in older 
adults, an age group where such infections are less common. A protective role for these 
PVL antibody levels is not clearly known and a better understanding of the reasons for less 
frequent PVL infections in this age group may identify factors beneficial in prevention of 
CA-MRSA infections. 
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Key Points 
Coded admissions data allows study of diagnoses in larger populations and for 
examination for changes over time. In such national Australian data, hospital admission 
numbers  for cutaneous abscess more than doubled in Australia between 1999 and 2014. 
Population rates of hospitalisation for this diagnosis increased in children, adolescents and 
younger adults but not in older adults. This was in the context of increases in CA-MRSA, 
which with PVL+ S. aureus are closely associated with pyogenic SSTI such as abscesses 
and occurrence in younger persons 
. 
PVL antibody levels increase with age and appear to reflect occurance of PVL associated 
infections. High levels were found in older adults who appear at lower risk of PVL+ S. 
aureus infections, but protective factors are not clearly established. 
Chapter 3 explores recent changes in S. aureus infection epidemiology by examing 
changes in SSTI hospital admissions (including for cutaneous abscessses) in Queensland 
children, with information on S. aureus as a cause and changes in antibiotic resistance 
(i.e. MRSA) from ICD-10 coding. 
 
 
 
 
 
 
 
 
 
 
 
29 
 
 
Chapter 3 
Changes in Staphylococcus aureus associated infections in Queensland children 
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Increased skin and soft tissue infection hospitalisations in Queensland children 
 
 
Abstract 
 
Aim 
Recent increases in paediatric admissions for skin and soft tissue infections have been 
reported in a number of countries and associated with changes in local Staphylococcus 
aureus infection epidemiology.  In Australia, the major recent change has been in the rise 
of community associated meticillin resistant S. aureus clones and this study analysed 
changes in paediatric hospitalisations for common skin infections in this context. 
 
Methods 
State-wide coded hospital admission data from Queensland children over the period 2000-
2011 were analysed for changes in admissions for common skin and soft tissue infections 
such as cutaneous abscesses and cellulitis. Available information on patient and infection 
characteristics such as S. aureus and antibiotic resistant bacteria as a cause was also 
studied. 
 
Results  
Yearly admission rates for common skin and soft tissue infections increased by around 
40% by the end of the study period, with resultant increases in total number of hospital 
admissions and hospital days of care.  S. aureus was a major cause of these infections 
and coded bacterial antibiotic resistance increased over the period.  
 
Conclusions  
Skin and soft tissue infection hospitalisations have increased over a short time period in 
Queensland, Australia children.  Concurrent changes in S. aureus infection epidemiology, 
including increases in community associated meticillin resistant S. aureus appear to be 
associated with these increases. 
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Introduction 
Treatment for SSTIs is common in both ambulatory and hospital care (142) and recent 
increases in treatment for SSTIs, including in children have been reported from a number 
of countries (107, 113, 143) including Australia (117).   
 
Staphylococcus aureus is a major cause of SSTIs (116) and a significant recent change in 
S. aureus epidemiology in Australia has been in the rise of CA-MRSA clones; with the 
commonest clone nationwide (47), ST93 being first described in the state of Queensland 
(41).  In the context of such reported changes in S. aureus and SSTI epidemiology, we 
sought to investigate recent changes in hospitalisations for SSTI in Queensland children 
and evidence for the role of CA-MRSA.  
 
Methods 
Information on hospital admissions in children (less than 18 years of age) from all hospitals 
in Queensland for the 11 year period July 2000 – June 2011 was obtained from the state 
health department (Queensland Health) that collates and reports these data for each 
financial year.  Data on each admission was from the International Classification of 
Diseases 10th Edition Australian Modification (ICD-10 AM) coding of each episode (ICD-10 
AM second to seventh versions were in use during the data period) (144). Available 
information included demographic (age group, gender, self-identification as indigenous 
Australian (Aboriginal and Torres Strait Islander; ATSI)), length of stay (LOS) and 
diagnoses as per ICD-10 coding.  ATSI status is the routinely collected data on ethnicity 
and information on membership of other ethnic groups was not available (145). Information 
was available on admission episodes containing ICD-10 coded diagnoses associated with 
staphylococcal or associated infections such as SSTIs. Provision of data was approved by 
the Queensland Health Human Research Ethics Committee.  
 
Population rates for yearly admissions for common individual SSTIs that were the principal 
diagnosis for the admission (cutaneous abscess; ICD-10 code L02, cellulitis; LO3) and for 
typical SSTIs collectively (impetigo (L01), abscesses (L02), cellulitis (L03), acute 
lymphadenitis (L04), pilonidal cyst with abscess (L05), pyoderma and other skin or 
subcutaneous tissue infection (L08))  (122) were calculated and changes determined.  For 
admission episodes with a  principal diagnoses as noted above, the presence of the 
supplementary ICD-10 code B95.6 (S. aureus as the cause of diseases classified 
32 
 
 
elsewhere) was noted and episode coding for infection with relevant antibiotic resistant 
organisms were also determined (Z06.x bacterial agents resistant to antibiotics).  
 
Queensland population data were obtained from the ABS (146). Admission rates for 
cutaneous abscess and typical SSTIs collectively in indigenous Queensland children were 
also estimated using available population estimates and projections (147). Regional 
differences in admissions were estimated using Australian Standard Geographical 
Classification (ASGC) (148) statistical division and subdivision information on admission 
episodes with population by age and sex for region determined from ABS data (available 
2004, 2009 estimates) (149). Statistical analysis of count data were performed using 
negative binomial regression. Following initial analysis, time series modelling using ARIMA 
(1,0,0) (Autoregressive Integrated Moving Average) was performed on SSTI admissions 
rates to determine timing of changes in rates (IBM SPSS 23, 2015, Armonk NY, USA). 
 
Results 
Cutaneous Abscess Admissions 
In the 11 year period July 2000 – June 2011 there were 8306 hospital admission episodes 
for cutaneous abscess in Queensland children (0-17 years of age). Of these, 54% were in 
males and in 31% of episodes; the patient was identified as indigenous Australian. S. 
aureus was indicated as the infection cause by ICD-10 coding in 46%. 
 
The annual (based on the financial year) number of paediatric age admissions rose from 
652 (July 2000 – June 2001) to 1050 (July 2010 - June 2011), a 61% increase. As a rate 
of admissions in children, this rose from 70/100,000 to 98/100,000 in the same years. The 
total sum of the length of stays for the admissions rose from 1510 to 2425 days. The 
average LOS was 2.3 days (and median LOS 2 days) in both years. The admission rate 
rose significantly for 0-17 years olds (by incidence rate ratio [IRR] comparing the final year 
[2010-2011] with the base line year [2000-2001]; p<0.001) with IRR 1.52 (95% Confidence 
Interval (CI) 1.38-1.68).  This was also the case when considering 0-4 year olds separately 
as a group (IRR 1.52; 95% CI 1.28-1.79), 10-14 year olds (1.68; 95% CI 1.35-2.08) and 
15-17 year olds (2.25; 95% CI 1.81-2.80), but not for the 5-9 year old group (0.922; 95% 
CI 0.75-1.14). In 2000-2001, 8% of admission episodes had bacterial agents resistant to 
antibiotics indicated by the ICD-10 AM coding, this rose to 22% of episodes in the last 
year.  As a rate of yearly admissions with coding for antibiotic resistance, the increase was 
from 5.8/100,000 to 22.0/100,000 (IRR 4.0; 95% CI 3.0-5.5; p<0.001) [Figure 3]. 
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FIGURE 3:  
Hospitalisations per 100,000 population for cutaneous abscesses in Queensland children 
2000-2011.  Data series are by age bands (0-17, 0-4, 5-9, 10-14 and 15-17 years) and 
‘Resistance Code’ indicates rate of admissions additionally coded as due to an antibiotic 
resistant organism. Diamond shape () indicates year where admission rate is significantly 
greater than baseline year of that series (IRR >1; p ≤0.01). 
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Cellulitis Admissions 
In the 11 year period, there were 9358 hospital admission episodes with a principal 
diagnosis of cellulitis in Queensland children. Of these, 61% were in males and in 20% of 
episodes; the patient was identified as indigenous Australian. S. aureus was indicated as 
the infection cause by ICD-10 coding in 17%. 
 
 The yearly number of admissions rose 73% from 683 (July 2000 – June 2001) to 1182 
(July 2010 - June 2011).. As a rate of admissions in children, this rose from 73/100,000 to 
111/ 100,000 in the same years. The total yearly admission days rose from 1714 to 2867 
days. The average LOS was similar (2.5 and 2.4 days) with median LOS 2 days in both 
years. 
 
The admission rate rose significantly for 0-17 years (IRR 1.64; 95%; 95% CI 1.49-1.80).  
This was also the case when considering 0-4 year olds separately as a group (IRR 1.49; 
95% CI 1.29-1.74), 5-9 year olds (1.59; 95% CI 1.27-1.99), 10-14 year olds (1.83; 95% CI 
1.49-2.24) and 15-17 year olds (1.74; 95% CI 1.41-2.13).  
 
In the first year, in 4% of admission episodes, bacterial organisms resistant to antibiotics 
were indicated by the ICD-10 AM coding, this rose to 14% of episodes in the last year.  As 
a rate of yearly admissions with coding for antibiotic resistance, the increase was from 
3.8/100,000 to 19.8/100,000 population (IRR 6.89; 95% CI 4.02-11.82); p<0.001) [Figure 
4]. 
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FIGURE 4: 
Hospitalisations per 100,000 population for cellulitis in Queensland children 2000-2011.  
Data series are by age bands (0-17, 0-4, 5-9, 10-14 and 15-17 years) and ‘Resistance 
Code’ indicates rate of admissions additionally coded as due to an antibiotic resistant 
bacteria. Diamond shape () indicates year where admission rate is significantly greater 
than baseline year of that series (IRR > 1; p ≤0.01). 
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SSTI Admissions 
Combined admissions for impetigo (L01), abscesses (L02), cellulitis (L03), acute 
lymphadenitis (L04), pilonidal cyst with abscess (L05), pyoderma and other skin or 
subcutaneous tissue infection (L08) were analysed. There were 22514 admissions for 
these diagnoses over the included period, with 58% being in male and 23% in indigenous 
persons. The yearly number of admission episodes rose 60% from 1741 (July 2000 – June 
2001) to 2802 (July 2010 – June 2011). As a rate of admissions in children, this rose from 
188/100,000 to 263/100,000 in the same years (a 40% increase). Total yearly hospital 
days rose from 4308 to 6498 days. 
 
The admission rate rose significantly for 0-17 year olds with IRR 1.51 (95% Confidence 
Interval (CI) 1.43-1.61).  This was also the case when considering 0-4 year olds separately 
as a group (IRR 1.44; 95% CI 1.30-1.59), 10-14 year olds (1.64; 95% CI 1.43-1.88) and 
15-17 year olds (1.82; 95% CI 1.61-2.05), but not for 5-9 year olds (1.10; 95% CI 0.95-
1.26). 
 
In the first year, in 4% of admission episodes, bacterial organisms resistant to antibiotics 
were indicated by the ICD-10 AM coding, this rose to 11% of episodes in the last year.  As 
a rate of yearly admissions with coding for antibiotic resistance, the increase was from 
8.3/100,000 to 29.7/100,000   (IRR 3.87; 95% CI 3.02-4.96); p≤0.001) [Figure 5]. 
 
Interrupted time series modelling was performed for years around 2006-2007 (first year 
with significant increase from baseline year in regression model (0-17 year olds) as the 
tipping point.  Best fit was modelling interruption after 2005-2006, i.e. 2006-2007 was the 
first after the change increasing admission rates commenced.  Model fit was Stationary R-
squared 0.962 with increases in admission rates following that time point (p=0.004).  
[Figure 6]  
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FIGURE 5:  
Hospitalisations per 100,000 population for common SSTIs in Queensland children 2000-
2011.  Data series are by age bands (0-17, 0-4, 5-9, 10-14 and 15-17 years) and 
‘Resistance Code’ indicates rate of admissions additionally coded as due to an antibiotic 
resistant bacterial agent. Diamond shape () indicates year where admission rate 
significantly greater than baseline year of that series (IRR >1; p ≤0.01). 
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FIGURE 6: 
Interrupted time series ARIMA model of SSTI admission rates in Queensland children (0-
17 years). Interruption modelled between 2005-2006 and 2006-2007. Observed admission 
rate and model fitted rate with upper and lower 95% confidence limits are graphed. 
 
 
 
 
 
 
100 
150 
200 
250 
300 
A
d
m
i
s
s
i
o
n
s
 
p
e
r
 
1
0
0
,
0
0
0
 
SSTI Admissions Queensland Children 
ARIMA Model  
Observed 
Fit 
LCL 
UCL 
39 
 
 
Admissions in Indigenous Queensland Children 
Annual hospitalisation rates in indigenous children (0-17) for abscesses, cellulitis  and for 
total SSTI admissions are shown in Figure 7 A, B and C. Abscess admissions ranged from 
270/100,000-360/100,000 during the time period, cellulitis admissions ranged from 
187/100,000-263/100,000 and for SSTIs 575/100,000-705/100,000. Final year rates were 
not significantly different from the initial year for each of the categories.  
 
For abscesses admissions, episodes with bacteria resistant to antibiotics indicated by the 
ICD-10 AM coding were 2-6% in the first two years, but ≥18% from 2005-2006 onward 
(increased rate of admissions with this coding from 2005-2006 onwards, p <0.001). For 
cellulitis the figures for resistant bacteria varied and were between 7-11% for years 2000-
2005 and greater than 13% for later years except for 2008-2009 (10%). Years 2009-2010 
and 2010-2011 had higher rates than 2000-2001 (p <0.05). For SSTI, the figures were 2-
3% in first two years and ≥12% from 2004-2005 onwards (p <0.001). 
 
Rates of admission among indigenous children were several fold higher than that of the 
overall paediatric population. In the final year (2010-2011) of the data, the rate for abscess 
admissions was 347/100,000 compared with 99/100,000 in the overall population (IRR 
3.52; 95% CI 3.08-4.01, p <0.001). For cellulitis the figures were 246/100,000 and 
111/100,000 respectively (IRR 2.22; 95% CI: 1.91-2.57, p <0.001) and for SSTIs the 
figures were 705/100,000 and 263/100,000 (IRR 2.68; 95% CI: 2.46-2.93, p <0.001) 
[Figure 7 A, B & C]. 
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FIGURE 7A, B & C: Hospitalisation rates for Queensland indigenous children and all 
children for abscesses, cellulitis and for all SSTIs. 
 
 
Regional Variations in Admissions 
The population of South East Queensland (SEQ) makes up about two thirds of the 
Queensland population (150) and admission rates were estimated for this urban / 
suburban region and for the rest of Queensland (regional and rural).  
 
In 2005-2006, the estimated SEQ admission rate (0-17 year olds) for abscesses was 
41/100,000 and 125/100,000 for the rest of Queensland (where 44% of the admissions 
were in indigenous children). The data for all SSTI admissions was 137/100,000 and 
265/100,000 respectively.  For 2010-2011, abscess admission rates were 69/100,000 SEQ 
and rest of Queensland 149/100,000; IRR regional rate 2.15 of urban (95% CI: 1.90-2.42 
p<0.001; (42% of admissions in regional Queensland were in indigenous children)). The 
proportion classified as antibiotic resistant (by coding) was 26% urban and 19% rural. 
SSTI admissions rates (2010-2011) were 217/100,000 vs. 339/100,000; IRR regional rate 
greater than urban 1.56 (95% CI: 1.45-1.68 p <0.001). 
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Discussion 
This analysis of hospital admission data for common skin and soft tissue infections in 
Queensland children showed increases of around 60% in yearly admission numbers 
between 2000 and 2011, with increases occurring mainly in the second half of that period. 
The time series analysis model was consistent with increases commencing after 2005-
2006 and first apparent in 2006-2007. Increases were seen for abscess and cellulitis 
admissions individually and for common SSTIs considered together, where the result was 
hospitalisation rate increases of around 40% in the paediatric population.  
 
Within the paediatric age group, baseline and later admission rates varied with age group.  
Infants and young children had highest baseline admission rates.  Increases (for abscess 
and SSTI admission rates) were noted in this age range (0-4 years) and for 10-17 year 
olds but not in the 5-9 age range.  A similar pattern was seen in an earlier analysis of 
Australian abscess hospitalisation rates (117). The age related differences appear to 
indicate different propensities for abscess infection reflecting a more complex interplay 
between host and pathogens factors.  Likelihood of hospital admission would also be 
expected to vary by age and treatment required (e.g. surgical drainage). 
 
These changes in infection epidemiology appear to have had a health care system level 
impact. Combined SSTIs resulted in an additional approximately one thousand additional 
paediatric admissions and two thousand extra hospital days yearly (2010-2011 vs. 2000-
2001) in Queensland. Admissions for ‘cellulitis’ have been given a cost of $3,500 in the 
Australian National Hospital Cost Data Collection (151) and this figure informs  the cost 
impact of the additional SSTI admissions. Health system effects of increased paediatric 
SSTI hospitalisations, such as becoming an increased proportion of all paediatric 
hospitalisations, increased requirement for procedural treatment (incision and drainage) 
and increased associated costs have been previously reported (152). 
 
The reporting of S. aureus as an important cause of infections such as cutaneous 
abscesses is consistent with the known microbiology of such infections (116)  and places 
the changes in paediatric SSTI hospital admissions in context of recent changes in S. 
aureus epidemiology in Australia (47). Of interest has been the emergence of mostly PVL 
expressing CA-MRSA, with meticillin resistance increasing from 11.5%- 17.9% over 2000-
2012 in surveys of community onset S. aureus isolates (47) .  
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Increased coding for antibiotic resistance (8% to 22% in abscess admissions) is likely to 
reflect a role for such PVL+ CA-MRSA strains, with PVL+ S. aureus clones being closely 
associated with furunculosis (153).  Use of such codes (to which there have been some 
changes through the ICD-10-AM editions) is based on clinician note of antibiotic resistant 
bacteria in the medical record (114) and is unlikely to represent full ascertainment of 
MRSA infections.  Potential factors include whether or not samples were available or sent 
for laboratory testing and increased appreciation of CA-MRSA over the time period 
studied. Admissions coded for antibiotic resistance rose by year 2005-2006, while overall 
admission rates appeared to commence increasing slightly later (2006-2007 onward) in 
the data analysis. This could reflect earlier increased attention to antibiotic resistance 
coding, or possibly MRSA being present in limited fashion before broader dissemination in 
the community. It should be also noted that some changes (2002) to improve the antibiotic 
resistance codes available for coding in ICD-10AM have occurred (114).  Direct 
ascertainment of bacterial aetiology from laboratory results was not possible for this study 
and the ICD-10 coding results can be regarded as informative rather than definitive.  
However, there is evidence for S. aureus including CA-MRSA as a cause, with CA-MSSA 
clones also present.  
 
This study relied on routinely and regularly collected ICD-10 coded hospital admissions 
data for often S. aureus associated SSTIs to study infection epidemiology over time. Such 
coded data have been widely used in health and health care studies (123). However, they 
rely on consistent interpretations of medical record information (created by many different 
health practitioners) made over time. Additionally, hospitalisation data only allow the study 
of SSTIs that led to admissions and do not include the many that are treated in the 
community setting (18). However, even with such limitations, it is clear that there have 
been rapid and significant recent changes in SSTI epidemiology in Queensland children.  
 
Indigenous children made up around 7-8% of the Queensland paediatric population in the 
study time period (146, 147), but experienced a disproportionate 31% of abscess and 20% 
of cellulitis hospital admissions.  Their admission rate for abscesses and SSTI was several 
fold higher than in the overall paediatric population. However, the higher, relatively stable 
rates were seen over 2000-2011, without the increases in admission rates seen in the 
second half of the decade in the overall data. High rates of SSTIs have been previously 
reported in indigenous Australians in Queensland (124) and in indigenous communities 
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worldwide (4). Higher rates were also seen in admissions in regional Queensland 
residents versus urban.  Part of this difference may relate to geographic distribution of 
indigenous Queenslanders, with many of the cases in regional areas having occurred in 
indigenous children. 
 
Recent reports from NZ (with a similar population size to Queensland) indicate high and 
increasing SSTI admission rates in children, with highest rates seen in Maori 
(1488/100,000 for S. aureus SSTI in Auckland (154)) and Pacific Island ancestry children 
and positive correlation with socio-economic disadvantage (143, 154).  An NZ national 
study reports a paediatric SSTI (typical skin infections by ICD-10 principal diagnosis) 
admission rate of 264.9/100,000 in 0-14 year olds (2000-2007) (143).  The admission rate 
for these diagnoses from the Queensland data (0-14 year olds, averaged over the same 
time period) was 177/100,000, rising to 228/100,000 for 2010-2011, suggesting some 
relevance in comparing the findings.  Of note is the importance ascribed to CA-MSSA in 
the NZ studies (154, 155). 
 
Paediatric hospitalisations for common skin and soft tissue infections have increased in 
Queensland between 2000 and 2011. Changes in S. aureus epidemiology appear to have 
had a role including increases in antibiotic resistant strains (CA-MRSA).  These increases 
have had health and health system impacts and further consideration of their aetiology and 
possibilities for SSTI prevention would be worthwhile.  
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Key Points 
There have been significant increases in hospitalisations for SSTI in Queensland children 
between 2000 and 2011. S. aureus is a major cause of these infections and antibiotic 
resistance (MRSA) has risen 3-4 fold from ICD-10 coded data. Rates of admissions were 
higher in regional Queensland and markedly higher in indigenous Queensland children. 
 
Chapter 4 examines common community onset staphylococcal associated infections 
(including SSTIs) treated at a tertiary children’s hospital in Queensland and changes in 
MRSA over a period of time from laboratory result data, as well as examining genotypes 
and PVL carriage in S. aureus isolates causing SSTIs in children. 
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Chapter 4 
Changes at hospital level in S. aureus infections 
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Part A 
Increased meticillin resistance in common Staphylococcus aureus infections in 
children treated at an Australian hospital 
Abstract  
Aim             
The rise of Community Associated Meticillin Resistant Staphylococcus aureus clones has 
had a rapid and significant impact on the epidemiology of S. aureus infections. This study 
analysed recent changes in meticillin resistance in common, usually community onset S. 
aureus hospital treated infections in Australian children. 
 
Methods 
Coded hospital admission data on cutaneous abscesses, cellulitis, pyogenic arthritis and 
osteomyelitis episodes treated at a tertiary paediatric hospital in Brisbane, Queensland, 
Australia over the period 2000 to 2010 and laboratory results for these admissions was 
analysed for changes in S. aureus antibiotic resistance. 
 
Results 
Of 1371 analysed admissions, 55% were in males, the median age was 4.2 years with 
range 0 to 19 years. An associated culture of S. aureus was present in 39% of the 
admissions. Meticillin resistance in S. aureus isolates rose from 13% (95% Confidence 
Interval 9%-18%) for July 2000 to June 2005, to 32% (95% CI 27%-37%), July 2005 to 
June 2010, p<0.0001. Significant increases in the S. aureus meticillin resistance rate were 
seen in admissions for abscesses (18% to 38% p<0.001) and osteomyelitis (6.5% to 35% 
p=0.004). The likelihood of isolating MRSA was increased (p<0.005) in abscesses cases 
(Odds Ratio 2.2; 95% CI 1.3-3.6), indigenous patients (4.0; 95% CI 2.3-7.1) and in the 
second half of the decade (3.4; 95% CI 2.1-5.5). 
 
Conclusions 
Meticillin resistance in common S. aureus infections in Queensland, Australia, children 
rose rapidly in the second half of the decade 2000-2010. Ongoing local monitoring of such 
changes is required to inform treatment decisions and to promote consideration of 
prevention strategies.  
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Introduction 
Staphylococcus aureus is a frequent cause of SSTI and also of the osteoarticular 
infections (OAIs) osteomyelitis and septic arthritis in children (156). Until recently, S. 
aureus isolates causing these infections with community onset were generally susceptible 
to anti-staphylococcal ß lactam antibiotics which feature in many empiric antibiotic 
treatment recommendations (157). Meticillin resistance in S. aureus is encoded by the 
acquired genetic element mecA  that results in resistance to all ß lactam antibiotics with 
the exception of the new ‘anti-MRSA’ cephalosporins (2).  
 
Meticillin resistant clones of S. aureus circulating in the community have rapidly become 
important causes of infection in a number of regions worldwide within the past 15 years. 
Many of these clones possess the putative virulence factor PVL, closely linked to pyogenic 
infections (e.g. abscesses) (4, 10). In the USA for example, contemporary paediatric data 
(111), showed MRSA infections have driven increases in hospital admissions for S. aureus 
infections.   
The rise of CA-MRSA has been well documented in Australia (6). Following early 
descriptions in indigenous persons in remote areas of Western Australia and in the 
Northern Territory (‘WA-MRSA’ clones, mostly PVL negative), CA-MRSA infections were 
noted in East coast states in the late 1990’s (initially in persons of Polynesian ethnicity) 
and shown to be due to ST30-MRSA-IV (PVL positive), the South-West Pacific clone 
previously reported in NZ (6).  Subsequently, the new ‘Queensland’ clone ST93-MRSA-IV 
(PVL positive) was described in South East Queensland (41) and has gone on to become 
the predominant CA-MRSA clone in Australia (48).  
Cases of severe CA-MRSA disease, such as pneumonia, osteomyelitis and disseminated 
multifocal infections have been reported in Australian children (8, 9, 53, 158) and in a 
paediatric series from 2008 in Western Sydney, 20% of community onset S. aureus 
infections were due to CA-MRSA (56).  However, there are limited data on the impact of 
CA-MRSA on S. aureus infection epidemiology in Australian children and on the extent 
and time course of such changes. 
In Queensland, CA-MRSA infections in paediatric health care are no longer novel or 
uncommon.  This study sought to document the extent of and recent changes in meticillin 
resistance in common S. aureus infections seen in children admitted to a paediatric 
hospital in Brisbane, Australia. 
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Methods 
The study utilised data from the Royal Children’s Hospital (RCH), formerly one of two 
tertiary paediatric hospitals in Brisbane, Australia.  ICD-10AM coded hospital admissions 
data for the 10 year period July 2000 to June 2010 were searched retrospectively to obtain 
information on admissions for common infections frequently caused by S. aureus. 
Information on admissions with a coded principal diagnosis (PD) of cutaneous abscess 
(ICD-10 code L02), cellulitis (L03), osteomyelitis (M86) and pyogenic arthritis (M00) was 
extracted.  Patient demographics, admission data and ICD-10 coding information were 
available for each admission episode.  To avoid double counting of the same infection, 
only one admission for each osteoarticular infection (M86, M00) per patient was included.  
For SSTIs (L02, L03) multiple admissions for the same patient were included if >4 weeks 
apart. 
 
Additionally, microbiology test results associated with each admission were obtained from 
the state-wide public hospital laboratory information system (LIS).  Positive culture results 
from blood, tissue, pus and swab samples were included with the first relevant result used 
when there were multiple results (for example swabs for screening purposes were not 
included). Where patients had been transferred from another Queensland public hospital 
to the RCH, and pathology results were also available on the LIS, these were also 
included. The tests had been referred by treating clinicians at the time and were processed 
by conventional bacteriological techniques by a clinical microbiology laboratory. S. aureus 
antimicrobial susceptibility testing was performed by Vitek1 or Vitek2 (bioMerieux) using 
Clinical and Laboratory Standards Institute (CLSI) interpretive criteria or by the CLSI disc 
susceptibility method. The methods use oxacillin and cefoxitin as regents antibiotics to 
determine meticillin susceptibility  (159). Information on positive microbial cultures 
associated with each episode was collated and for S. aureus results, meticillin resistance 
noted.  For MRSA isolates, sensitivities to non-β-lactam antibiotics were noted and isolates 
were classified as multiresistant MRSA if resistant to at least two of erythromycin, 
gentamicin and tetracycline (50) and non-multiresistant if this was not the case. Time of 
collection of sample relative to date of admission (in days) where S. aureus was isolated 
was determined to provide information on the likelihood of community versus hospital 
association of the infection. Collection within 2 days of admission was recorded, as 
occurrence of infection after 48 hours of admission is widely used as a measure of hospital 
rather than community acquisition (160). 
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For cases where S. aureus was isolated, factors associated with meticillin resistance were 
examined using two-tailed chi-square or Fisher’s exact tests (p<0.05 significant) to 
compare groups with 95% confidence intervals (CI) of proportions calculated using a 
Newcombe-Wilson based method (161).  To examine for changes in MRSA over time, 
comparisons were made between data from the earlier half (July 2000 - June 2005) and 
the later half (July 2005 – June 2010) of the period studied. This was chosen as a simple 
comparison in the setting where MRSA was thought to have increased through the time 
period studied. Following initial univariate analysis, factors with p<0.2 were used in binary 
logistic regression multivariate analysis (forced entry method) using IBM SPSS 21 to 
further examine associations of meticillin resistance. The number of admissions for the 
diagnoses being studied was also examined as a rate per all hospital admissions for the 
periods July 2000 - June 2005 and July 2005 – June 2010 with CIs for rates determined 
using Byar approximation of the Poisson distribution (161). 
Study approval was obtained from the Queensland Children’s Health Services Ethics 
Committee, RCH Executive, Queensland Health Clinical and Statewide Services Research 
Committee and the Queensland Health Office of Health and Medical Research. 
Results 
A total of 1371 admission episodes were included in the analysis.  These included 412 
admissions for abscess, 633 for cellulitis, 101 for pyogenic arthritis and 225 for 
osteomyelitis.  These were in 754 (55%) males and 617 (45%) females with a median age 
of 4.2 years (range 0-19.1 years). In 9.3% of admissions, the patient was coded as being 
of indigenous ancestry. Admission rates per 10,000 hospital admissions were for 
abscesses 19 (95% CI 16-22)/10,000 (July 2000 – June 2005) and 27 (95% CI 23-
30)/10,000 (July 2005 – June 2010). For cellulitis, over the same time periods, 30 (95% CI 
27-34)/10,000 and 40 (95% CI 36-44)/10,000, for septic arthritis 5 (95% CI 4-7)/10,000 
and 6 (95% CI 5-8)/10,000 and for osteomyelitis 11 (95% CI 9-14)/10,000 and 14 (95% CI 
12-16)/10,000. 
 
Overall, in 39% (536/1371) of admissions S. aureus had been cultured from a patient 
sample. Samples had been collected within two days of the hospital admission date in 
87% of cases where S. aureus was cultured. Over the decade 2000-2010, 25% of all S. 
aureus isolates were MRSA.  In the first half of the decade (July 2000 to June 2005) this 
proportion was 13% (95% CI 9%-18%) and in the second half (July 2005 to June 2010) 
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32% (95% CI 27%-37%; p<0.0001). Admission numbers by time period, diagnosis and 
proportion by diagnosis for each time period are provided in Table 2. The proportions of 
admissions for the different diagnoses within each time period were similar. 
Over the decade, indigenous patients accounted for 26% (34/133) of the admissions from 
which MRSA was isolated and 8% of admissions in which MSSA was isolated (32/403).  
Within the group of indigenous patients from whom S. aureus was isolated, 52% (34/66) 
were MRSA. Indigenous status was associated with increased proportion of MRSA 
compared to cases in non-indigenous patients (p<0.001). 
TABLE 2: Admission numbers by time period and diagnosis  
Admissions   Period 
  Total July 2000-June 2005 July 2005-June 2010 
Abscess 412 160 29%
1 
252 31% 
Cellulitis 633 254 46% 379 46% 
Pyogenic Arthritis 101 44 8% 57 7% 
Osteomyelitis 225 94 17% 131 16% 
  1371 552   819   
1Diagnosis as percentage of admissions for that time period (italics) 
 
Cutaneous abscess (L02) 
The 412 episodes with principal diagnosis of abscess occurred in 209 males and 203 
females with a median age of 3.6 years (range 0-17.8 years).  S. aureus was cultured from 
a patient derived specimen in 70% of admissions, another organism was cultured in 11% 
and in the remaining 19% there was no growth or a sample was not recorded. There were 
160 admissions (39% of total) in the first half of the decade and 252 (61%) in the second. 
Overall, 31% of the S. aureus isolates were MRSA. However, the proportion increased 
from 18% (95% CI 12-26%) in the first half of the decade to 38% (95% CI 32-46%) in the 
second (p<0.0005). In the latter period 28% of all abscess admissions were due to MRSA. 
Furthermore, in the last year (2009-2010) 45% of S. aureus causing abscesses were 
MRSA and MRSA caused 35% of all abscess admissions. Figure 8 shows trends in 
admissions for abscesses and in proportions due to MRSA. 
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FIGURE 8: Abscess admissions, by year and S. aureus antibiotic susceptibility (MSSA, 
MRSA). Proportion of S. aureus (%) MRSA indicated on right axis. 
 
Cellulitis (L03) 
Of the 633 episodes with principal diagnosis of cellulitis, 344 occurred in male patients and 
289 in females. Median age was 4.1 (range 0-17.8) years.  In 64% of admissions there 
was no positive culture result. S. aureus was cultured in 25% and another organism in 
10%.  There were 254 admissions (40% of total) from July 2000 to June 2005 and 379 
(60%) from July 2005 to June 2010. Over the decade, 16% of the S. aureus isolates were 
MRSA, this proportion was 10% (95% CI 5-21%) in the first half of the decade and 20% in 
the second (95% CI 13-29%)   (p=0.13).  
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Pyogenic arthritis (M00) 
A total of 101 cases had been coded with a principal diagnosis of pyogenic arthritis.  
These were in 61 males and 40 females, with median age 2.6 (0-14.4) years. S. aureus 
was cultured in 18 cases and another pathogen in 24 cases. There were no MRSA cases 
in the first half of the decade; in the second half, 3 of 9 S. aureus cases were MRSA 
(p=0.21). 
 
Osteomyelitis (M86) 
Over the decade, there were 225 osteomyelitis episodes identified by the search strategy. 
There were 140 males (62%) and 85 females (38%). The median age was 7.2 years (0-
19.1 years). S. aureus was cultured in 68 cases (30%). Culture negative episodes 
accounted for 57% and other organisms were found in 13%.  Only 2 of 31 S. aureus cases 
were MRSA in the first half of the decade, a rate of 6.5% (95% CI 2-21%), compared with 
13 of 37 or 35% (95% CI 22-51%) in the second half (p=0.007). 
 
MRSA Isolate Antibiotic Sensitivities 
All of the 133 MRSA isolates included were non-multiresistant. Erythromycin (and hence 
likely clindamycin) resistance was seen in 6% (162).  All 119 isolates for which a TMP-
SMX result was recorded were susceptible to that antibiotic. For agents with topical 
application, 2 of the 133 isolates were recorded as fusidic acid resistant with the rest 
susceptible.  Mupirocin susceptibility result was available for 49 isolates, with 1 resistant 
(result routinely available from late 2008) and for chloramphenicol, results for 65 isolates, 
with 1 resistant.  
 
Logistic Regression Analysis 
Factors associated with culturing MRSA (compared with MSSA) were examined using 
logistic regression analysis. The independent variables sex (female), ATSI status, time 
period (2000-2005 or 2005-2010) and type of infection (compared to cellulitis) were subject 
to univariate analysis with MRSA associated with abscesses, ATSI persons and the later 
time period (Table 3). Factors from this analysis with p<0.2, infection type, indigenous 
status and time period, were used to create a multivariate model. The multivariate model 
was statistically significant, chi-square value = 62.0 (5, n=536), p<0.005 and correctly 
classified 78% of cases.  The likelihood of isolating MRSA was increased in abscess 
cases compared with cellulitis cases (Odds Ratio 2.2; 95% CI 1.3-3.6), indigenous patients 
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(4.0; 95% CI 2.3-7.1) and in the second half of the decade (3.4; 95% CI 2.1-5.5) all 
p<0.005. 
 
TABLE 3.  Univariate Analysis – Association of factors with MRSA 
            
 Factors Odds 
Ratio 
95% C.I. Of Odds Ratio Significance 
(p value) 
Lower Upper 
  
Sex (F) 0.85 0.58 1.6 0.43 
Abscesses 2.28 1.4 3.72 0.001 
OM 1.46 0.72 2.97 0.3 
SA 1.03 0.28 3.82 0.96 
ATSI 3.98 2.34 6.77 0.001 
2005-2010 3.17 1.99 5.05 0.001 
 
Discussion 
S. aureus frequently causes cutaneous abscesses, cellulitis, pyogenic arthritis and 
osteomyelitis in children.  In this analysis of hospital admissions for these infections at a 
single tertiary paediatric hospital in Brisbane, Australia, the proportion of S. aureus that 
was meticillin resistant more than doubled from 13% to 32% from the first to the second 
half of the decade 2000-2010. Increases in meticillin resistance were seen particularly in 
abscesses (18% to 38%) and osteomyelitis (6.5% to 35%). These increases occurred 
rapidly, particularly in the second half of the decade and occurred in the context of known 
increases in CA-MRSA infections in Queensland (50).  
 
In approximately 10% of admissions the patient was identified as being of indigenous 
ancestry. This likely indicates some over-representation as 7-8% of Queensland children 
are indigenous (146, 147). This is in the context of the younger indigenous population 
structure, with 48% aged ≤19 years compared with 26% in the non-indigenous population 
(163). Indigenous patients were over-represented in MRSA infections – accounting for 
26% of all MRSA infections and having a meticillin resistance rate of 52%. However, it 
should be noted that 74% of all MRSA infections occurred in non-indigenous persons. 
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 Additionally, admissions for abscesses and cellulitis appeared to rise as a rate per 10,000 
hospital admissions from the first half to the second half of the decade, consistent with 
Queensland population level increases for SSTI admissions in children reported in Chapter 
3. 
S. aureus is the commonest cause of cutaneous abscesses (116) and in this series S. 
aureus was cultured in 70%.  CA-MRSA clones have been particularly associated with 
abscesses and hence the rise in meticillin resistance in abscess admissions is consistent 
with the local dissemination of CA-MRSA clones. In the period 2005-2010, 28% of all 
abscess admissions were due to MRSA and comparable with an earlier Australian 
emergency department abscess series where 30% were due to non-multiresistant MRSA 
(51).  
The majority (64%) of cellulitis admissions did not have a possible pathogen cultured. This 
difficultly in demonstrating the microbial cause of a particular cellulitis episode is 
recognised (164) and it should be noted that the positive cultures obtained (from surface 
swabs) may not reflect the actual pathogen. Nevertheless, S. aureus was isolated in 25% 
of episodes; 16% of these were MRSA. 
The proportion of OAIs with a positive culture (43%; 62% of which due to S. aureus) was 
comparable to that in a previous (1998-2002) Australian series (55) (42% culture positive 
of which 73% were S. aureus). However, the striking difference was the increase in MRSA 
(21% of S. aureus isolates; 35% in the second half of the decade) compared to 11% in the 
earlier series. 
Increased likelihood of isolating MRSA was noted in cases of abscesses and in indigenous 
patients and these are known risk factors for CA-MRSA (4, 51). The increased risk in the 
second half of the decade was consistent with increases in CA-MRSA seen with the 
epidemic dissemination of CA-MRSA clones. The identification of these as significant 
factors is strengthened by the multivariate analysis, which can control for possible 
confounding between variables (where the variables are considered) (165).  However, 
other potentially relevant factors such as previous personal and household member 
cutaneous infections, prior antibiotics, socio-economic status and any residual 
confounding (143) were not able to be explored due to lack of data. 
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This study used a combination of ICD-10 coded hospital admission data and laboratory 
result information that allowed analysis of >1300 admission episodes that had occurred 
over a decade. Given the large number of cases, detailed case review of each admission 
episode was not performed. Information on factors such as prior antibiotic administration  
which might have relevance to risk for MRSA, or likelihood of obtaining a positive culture 
result, or severity measures such a requirement for multiple procedures or intensive care 
admission were not available for analysis.  It was also not possible to definitively identify 
episodes as community or hospital onset as linked information such as on presence of 
symptoms on hospital admission or recent surgery or hospital admission was not 
available.  However, the majority of SSTIs and OAIs in children in this series would be 
expected to be of community onset as they were the reason for hospital admission (coded 
principal diagnosis). Additionally, in 87% of episodes where S. aureus was cultured, the 
date of sample collection was within two days of the admission date, suggesting 
community rather than hospital onset of infection. The significance of the bacterial isolate 
result in a particular admission would be expected to vary.  Blood, tissue or joint samples 
in OAIs or pus samples from abscesses would be expected to identify causative 
pathogens; however, the significance of a surface swab in cellulitis would be less certain.  
S. aureus isolate genotype data were unavailable, however, the MRSA isolates were ‘non-
multiresistant MRSA’ and these sensitivities were consistent with the common CA-MRSA 
clones seen in Australia. The conclusion that PVL+ CA-MRSA clones were likely causes is 
also based on published reports on S. aureus trends in Queensland (50) and in Australia 
(48) and similar paediatric reports from other geographic regions (111, 166).  
Additionally the study looked at infections that resulted in hospital admissions to a tertiary 
paediatric hospital. There may be differences in S. aureus infections treated in ambulatory 
care and given the tertiary hospital setting, patterns of referral may influence the spectrum 
(e.g. severity) of infections seen. 
This study reports rapid increases in meticillin resistance in common, usually community 
onset paediatric S. aureus infections in Queensland children and is against the 
background of the emergence of epidemic CA-MRSA clones in Australia and in other 
countries (4, 16). Given the increase in MRSA - from 13% to 32% in this series, empiric 
antibiotic choices for these common infections need to be reconsidered, as well as 
definitive management including the need for surgical (drainage) procedures where 
appropriate.  In the context of high rates of MRSA, treatment options for SSTIs include 
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drainage (e.g. for abscesses) and antibiotics such as clindamycin and TMP-SMX where 
indicated (68, 69, 71). These antibiotic options would appear appropriate given the high 
rates of susceptibility to these antibiotics in the MRSA isolates from the infections studied. 
Limited information was available on susceptibility to some topical agents such as 
mupirocin in these isolates, but with minimal resistance recorded.  
While flucloxacillin is still recommended for empiric treatment of osteomyelitis by a recent 
version of a widely used Australian treatment guideline (167), the guideline specifically 
makes note of increases in CA-MRSA and advises patient and local factors be taken into 
account when choosing treatment, with consideration given to vancomycin or clindamycin 
as appropriate. The frequency and risks for MRSA identified in this study are relevant 
when making treatment choices for Queensland children with suspected S. aureus 
infection. 
The rapidity of these changes in meticillin resistance emphasises the importance of 
continuous local monitoring of changes in the epidemiology of S. aureus infections and in 
applying this information to direct changes in management and in efforts to prevent such 
infections. 
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Chapter 4 
 
 
Part B 
 
Genotyping by whole genome sequencing of S. aureus isolates from skin and soft 
tissue infections at a children’s hospital. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
59 
 
 
Introduction 
S. aureus isolates causing infections are often described as belonging to a particular 
clone. This reflects the population structure of S. aureus (39). Clones are genetically 
similar (core genome) with the implication of descent from a common recent ancestor. 
Larger scale genetic recombination events (genetic exchange) are relatively uncommon. 
Such S. aureus clones are defined by sequence type determined by MLST, based on 
(having identical) gene sequences at multiple (7) conserved regions of the genome.  
Additionally, clones may be described as MRSA (with SCCmec type) and containing 
factors such as PVL, as well as typing by many other genetic features (168).   
 
Typing information can also be determined from analysis of the sequences from the whole 
bacterial genome. Whole genome sequencing (WGS) of bacteria has become much more 
accessible with developments in technology within the last 5 years. ‘Bench-top’ size 
instrumentation suitable for use in clinical laboratories and the rapidly decreasing cost of 
sequencing has brought this technology into consideration (169) and applications relevant 
to health care are actively being explored (170).  Potential uses include in determining 
antibiotic resistance, investigation of nosocomial (and other) outbreaks and in 
understanding pathogen virulence and other characteristics (171). Clinical laboratories 
may already perform such investigations by other methods, for example of nosocomial 
outbreaks and the new technologies may come to enable and enhance these functions. 
One such WGS technology, Ilumina MiSeq sequencing, involves fragmenting DNA, to 
which (end) adapters are then applied. Fluorescent signals are released as these DNA 
templates are re-synthesized, allowing determination of the nucleic acid sequence of the 
fragment and this process occurs in a parallel fashion across many fragments (169). For 
data analysis, fragments can be mapped to a reference genome (170). In this study, as 
part of development of an application method for WGS and analysis of S. aureus isolates 
in a clinical health laboratory setting, basic genotyping on a set of isolates was performed 
and this process was applied to a small collection of paediatric SSTI S. aureus isolates 
from a children’s hospital in Brisbane, Queensland, Australia. 
 
Method 
Bacterial isolates: S. aureus isolated from routine clinical samples from children, referred 
from the tertiary children’s hospital in Brisbane, Queensland (LCCH) to the state pathology 
provider (Pathology Queensland) were collected over a month long period (October 2015).  
Isolates likely to represent community onset infections (collection from ED or within 2 days 
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of hospital admission) with clinical information suggestive of SSTI (such as ‘abscess’, ‘pus’ 
or ‘cellulitis’) were used. Isolates had undergone antimicrobial susceptibility testing using 
the Vitek 2 system (bioMerieux Marcy-l'Étoile, France).  Ethics approval was provided by 
the Queensland Children’s Health Services Ethics Committee. 
Isolates were stored frozen at -80°C, then subcultured onto Luria agar and incubated at 
37°C. Colonies were harvested after 24 hours incubation and bacterial DNA extracted 
using the EZI DNA tissue kit (Qiagen, Hilden, Germany). Sequencing libraries were 
prepared using Nextera XT chemistry (Ilumina Inc, San Diego, CA, USA) for a 150 base 
pair (bp) paired end sequencing run on an Ilumina MiSeq sequencer (performed on site at 
a clinical pathology laboratory). 
Sequences were then analysed using CLC Genomics Workbench software version 8.5 
(CLC bio, Aarhus, Denmark). Sequences were matched (separately) to two S. aureus 
reference genomes (MRSA252; NCBI Reference Sequence: BX571856.1 and MW2; 
NC_003923.1) for analysis. MSLT Sequence Type was assigned using alleles from 
http://saureus.mlst.net/. In silico PCR was performed for the presence of mec and pvl 
genes and SSCmec typing (172-174). 
 
Results 
Analysis was performed on 24 SSTI S. aureus isolates from 15 males and 9 females, with 
median age 5 years and 7 months (age range 2 weeks to 16 years). Six isolates (25%) 
were MRSA (mecA gene present) and this was concordant with the phenotypic 
susceptibilities (and mecA was absent in all MSSA isolates). Furthermore 13 (54%) of the 
24 isolates had the PVL gene present (PVL+; including all MRSA isolates). Of the six 
MRSA isolates, five were ST-93 MRSA PVL+. These ST-93 isolates were all typed as 
SCCmec IVa. Twelve different STs were identified in the isolate collection. See Table 4 
which also contains isolate susceptibility to clindamycin (71% of isolates) and TMP-SMX 
(100%) and clinical information. 
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TABLE 4:  SSTI S. aureus isolate information 
 
Isolate:           
Sequence  mecA PVL Clinda- TMP- Clinical 
Type Status Gene mycin SMXb Information 
1 MSSA PVL+ S S purulent cellulitis knee 
1 MSSA PVL+ S S abscess - buttock 
1 MSSA PVL+ S S abscess - leg 
1 MSSA PVL+ S S abscess - neck 
5 MRSA PVL+ S S vesicle -  pinna (ear) 
5 MSSA PVL- S S boil - thumb 
6 MSSA PVL- S S cellulitis - knee 
8 MSSA PVL- R S cellulitis - toe 
15 MSSA PVL- S S cellulitis -thumb 
25 MSSA PVL- S S discharge - umbilicus 
30 MSSA PVL- R S abscess - buttock 
72 MSSA PVL- S S pustule - abdomen 
93 MRSA PVL+ S S pustule  - torso 
93 MRSA PVL+ S S spider bite - leg 
93 MRSA PVL+ S S abscess - buttock 
93 MRSA PVL+ R S boil - back 
93 MRSA PVL+ S S abscess  - eyelid 
121 MSSA PVL+ S S abscess + cellulitis - face 
188 MSSA PVL- S S cellulitis - buttock 
2276 MSSA PVL- R S abscess - abdomen 
2276 MSSA PVL- R S impetigo - hand 
unassigneda MSSA PVL+ R S abscess - buttock 
unassigned MSSA PVL+ S S abscess + cellulitis - foot 
unassigned MSSA PVL- R S cellulitis -ankle 
aUnassigned ST – isolates differed at one MLST allele from known STs, i.e. single 
locus variants (SLV). bTMP-SMX - trimethoprim-sulfamethoxazole 
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Discussion 
In this study of a small collection of paediatric SSTI S. aureus isolates, a  quarter were 
MRSA and these were mostly identified as ST93-MRSA PVL+, and this was consistent 
with this clone’s status as the most common CA-MRSA in Australia (47). Of note was the 
presence of the PVL gene in 13 of 24 isolates, being present in both MRSA and (in 7 of 
18) MSSA isolates. These findings of CA-MRSA and PVL+ S. aureus being present in 
paediatric SSTI isolates are in keeping with their known association with SSTI and 
presence in younger persons (10, 66). Clindamycin and TMP-SMX have been used to 
treat SSTIs in the context of significant S. aureus meticillin resistance (69, 71); however, 
these results indicate the importance of locally monitoring susceptibility to empirically 
recommended anti-staphylococcal antibiotics as 7 of 24 isolates (6 MSSA) were non-
susceptible to clindamycin. While antibiotics may not be required to treat incised and 
drained abscesses (68), and the role of clindamycin resistance is not clear in clindamycin 
treatment failure of SSTIs (71), appropriate empiric treatment choices may be of 
importance when treating what are thought to be severe or invasive S. aureus infections. 
 
PVL+ S. aureus clones have been particularly linked with purulent SSTI (10) and the 
limited available clinical information on the study isolates is consistent with this, with the 
PVL+ isolates often causing abscesses or being associated with the presence of pus. A 
comparison between PVL + and PVL – strains was not done due to the small number of 
isolates, but such studies have shown an association of PVL+ isolates with abscesses 
(66).  CA-MRSA strains causing buttock abscesses as a common site of infection in 
children has been noted (175).  Despite the strong epidemiologic linkage, the actual role of 
PVL toxin in the aetiology of SSTI is not clear, with variable findings reported in animal 
studies (176) and PVL antibody reported as not protective against SSTI recurrence in a 
paediatric population (135).  Secreted staphylococcal toxins (including alpha toxin) are 
thought to play a role however (176).  
 
Detailed information on CA-MRSA clones circulating in Australia is available (47), 
however, there is less information on SSTI MSSA isolates (177).  A recent study (which 
included adults) of community onset S. aureus infections (almost all SSTI) in Melbourne, 
Australia found PVL genes present in 16% of MSSA from a variety of STs (178). In the 
Melbourne study, S. aureus isolates (MRSA and MSSA) came from > 20 MLST/SCCmec 
types and diversity was also seen in the local isolates in which 12 different STs were 
assigned among 24 isolates.  In other reports, PVL was present in 37% of MSSA isolates 
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in an Auckland, NZ hospital series (125) in 42% in a South African hospital series (179) 
and in 30% in a Saudi Arabian hospital series (180). Higher rates have been reported in 
paediatric series, 68% at a Columbian paediatric hospital (181) and 54% in Auckland, NZ 
(182). 
 
The isolate collection analysed was a small set of ‘convenience’ isolates collected from a 
diagnostic laboratory from referrals from a children’s hospital over a short period of time 
and analysed as part of a method development process in small numbers due to 
limitations of practicality and cost. Analysis of WGS data was applied to basic genotyping 
of isolates.  The results from the isolate collection are indicative rather than definitive of the 
nature and number of different S. aureus clones causing infection in the referral population 
studied and should be interpreted as such. Clinical information was limited to electronically 
provided diagnosis information and detailed clinical features or treatment information was 
not available for correlation with S. aureus genotype. 
 
Additionally, WGS can be used for detailed examinations of isolate antimicrobial 
resistance, virulence and regulatory factors, to determine epidemiological relatedness and 
changes over time (171, 183) and these applications are very much of current interest.  
Accordingly, with increased availability and continued decreases in cost, WGS could be 
applied to isolate characterisation for surveys or monitoring of S. aureus infections in 
smaller scale or local studies, as well as larger regional or national surveys and the 
method can also be applied to clinical studies of infection. WGS could be used in place of 
current methods for molecular epidemiology or genotyping such as multiple or multiplex 
PCRs (e.g. for PVL, mecA, SCCmec typing), sequencing of multiple loci for sequence type 
assignment (i.e. MLST) or PGFE. Once methods for performing WGS on bacteria and 
analysing data are developed, one experimental method can be performed (rather than 
multiple assays) and extended analysis can then be performed relatively efficiently.   As 
such WGS may come to match and better the time frame, cost and utility of these other 
methods, in addition to allowing scope for greater analysis. 
 
In summary, genotyping by WGS was applied to SSTI S. aureus isolates from children in 
Queensland and confirmed the importance of CA-MRSA clones, as well as the high 
prevalence of PVL genes in both MSSA and MRSA isolates causing such infections.  
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Key Points 
Meticillin resistance in common S. aureus associated infections increased from 13% to 
32% over the period 2000-2010 at a tertiary paediatric in Queensland. The increases in 
MRSA were seen particularly in abscesses and, in the second half of the decade studied, 
with MRSA particularly present in indigenous children. These findings document the 
rapidity and time frame (2005 onwards) of the rise in CA-MRSA in the paediatric 
population serviced by the tertiary hospital. ST-93 MRSA IVa PVL+, the dominant CA-
MRSA clone in Australia was identified as a cause of SSTI in isolates studied (from a later 
period) at the same hospital service and the presence of PVL in both MRSA and MSSA 
isolates was noted.  
The need to monitor S. aureus infection epidemiology and make changes in treatment 
guidelines in the face of what can be rapid changes in antibiotic resistance is highlighted 
by these findings and new methods such as WGS may find increasing application in 
monitoring and understanding such infections. 
Chapter 5 reports on a finding of CA-MRSA as a cause of serious eye infections at the 
same tertiary paediatric hospital during the time period rapid increases in CA-MRSA were 
noted as well as examining world-wide literature reports of S. aureus bacteraemia in 
children and the differences noted, including in meticillin resistance, over time and in 
different regions and patient populations. 
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Chapter 5 
S. aureus infections: specific clinical manifestations 
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Part A 
Ocular Infections 
 
Published Article:  
Vaska, VL.et al. Community-associated meticillin-resistant Staphylococcus aureus causing 
orbital cellulitis in Australian children. The Pediatric Infectious Disease Journal. 
2011;30(11), 1003-1006. 
 
COMMUNITY-ASSOCIATED METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS 
CAUSING ORBITAL CELLULITIS IN AUSTRALIAN CHILDREN 
Vikram L. Vaska, FRACP, FRCPA 
Keith Grimwood, MD, FRACP 
 Glen A. Gole, MD, FRANZCO 
Graeme R. Nimmo, MD, FRCPA 
David L. Paterson, PhD, FRACP, FRCPA, 
Michael D. Nissen, FRACP, FRCPA 
Abstract: Community-associated meticillin-resistant Staphylococcus aureus has only 
emerged recently as a cause of serious ocular infections in several different countries. At a 
tertiary paediatric hospital in Brisbane, Australia, community-associated meticillin-resistant 
S. aureus orbital cellulitis was first noted in 2009. Since then, it has caused 4 of 9 such 
infections. 
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Introduction 
Most cases of orbital cellulitis result from spread of infection from an adjacent sinus, 
although they can occasionally follow penetrating trauma, nearby skin infection or 
bacteraemia. Important etiologic pathogens are Staphylococcus aureus, nontypeable 
Haemophilus influenzae, Streptococcus (Str.) species, including Str. pneumoniae, and 
anaerobes in older children. Management involves intravenous (IV) antibiotics (with β 
lactam antibiotics first line empiric recommendations (184)) and often surgery for 
underlying sinus disease or orbital collections. A notable recent development in S. aureus 
epidemiology is the global emergence of community-associated meticillin-resistant S. 
aureus (CA-MRSA) clones. They usually possess SCCmec allotypes IV or V and the 
virulence factor Panton–Valentine leukocidin (PVL) which can cause tissue necrosis. The 
appearance of CA-MRSA has been accompanied by increased rates of skin and soft-
tissue infections and of severe, invasive disease. In Australia, CA-MRSA was first 
described in the 1980s in remote areas of Western Australia. In the late 1990s in 
Queensland, infections in persons of Polynesian ethnicity were shown to be from 
sequence type (ST) 30-MRSA-IV, the South-West Pacific clone reported previously in NZ. 
Subsequently, a new “Queensland” clone ST93-MRSA-IV was recognized as the 
predominant Australian clone (6). A 2008 Queensland survey found 15% of S. aureus 
clinical isolates to be CA-MRSA (124). Following our observation of 4 cases of CA-MRSA 
orbital cellulitis initially treated with β lactam antibiotics, we examined their medical 
records, reviewed the microbiology of treated cases of orbital cellulitis in the previous 10 
years and searched the literature for CA-MRSA as a cause of serious ocular infections in 
children. 
 
Methods 
Setting. The Royal Children’s Hospital (RCH), Brisbane is 1 of 2 tertiary paediatric 
hospitals in the state of Queensland, Australia. The Queensland Children’s Health 
Services District Ethics Committee approved the study. 
 
CA-MRSA Orbital Cellulitis Cases. Data were collected on those cases (January 2009–
June 2010) on which the RCH Infectious Diseases Unit had consulted. 
Orbital Cellulitis Cases. All cases treated at RCH between July 2000 and June 2010 were 
identified by International Classification of Diseases-10 Australian Modification (ICD-10 
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AM) code (H05.0) search. Case demographic, clinical and microbiologic data were 
retrieved. 
Microbiology. Blood cultures, operative and pus specimens collected as part of usual 
clinical care were analysed by the Pathology Queensland Central Laboratory using routine 
bacteriologic methods. CA-MRSA isolate genotyping was performed by single nucleotide 
polymorphism and binary gene typing (185). 
Statistics. Fisher exact test was applied to CA-MRSA case numbers. 
Literature Review. OVID Medline (1948 onward; MeSH and keyword search) and Embase 
(1966 onward; “extensive search”) databases were searched (April 2011) for “orbital 
cellulitis” or “orbital diseases” or “eye infections, bacterial” and “meticillin.” Articles with 
clear cases of paediatric (<18 years) CA-MRSA ocular infections were then identified. 
Bibliographies of included articles were also examined. Cases were not included where 
ocular involvement was either uncertain, not the primary, or presenting infection or 
involved preterm neonates. 
Results 
CA-MRSA Cases. 
Case 1. A 13-year-old boy presented with 24 hours of right periorbital swelling, pain, and 
fever after 3 days of coryza and headache. Orbital computerized tomography (CT) showed 
right sided opacification of sinuses, proptosis, and edema of the preseptal soft tissues and 
of the intraorbital fat (mainly in the roof of the orbit) with displacement of the superior 
rectus muscle, but no subperiosteal collection. Flucloxacillin and ceftriaxone therapy was 
commenced. On the third hospital day MRSA was identified in blood cultures. The 
antibiotics were changed to IV vancomycin and lincomycin and within 2 days he was much 
improved. The IV antibiotics were continued for 7 days, followed by 14 days of oral 
clindamycin with good effect. The S. aureus blood culture isolate was resistant to β-lactam 
antibiotics and erythromycin, but there was no inducible clindamycin resistance. Genotype 
was clonal complex (CC) 30-MRSA; PVL positive (i.e., ST30-MRSA-IV, the South West 
Pacific Clone). 
Case 2. A 4-year-old girl presented with 24 hours of bilateral periorbital swelling and fever 
following coryzal symptoms. A sibling had experienced repeated episodes of pyoderma. 
CT scans showed pansinusitis and a subperiosteal collection in the medial right orbit with 
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rarefaction of the right lamina papyracea. Initial treatment with flucloxacillin and ceftriaxone 
was changed to vancomycin for 5 days, then lincomycin for 6 weeks, followed by 2 months 
of oral clindamycin. She underwent 2 drainage procedures of the maxillary sinus and 
subperiosteal collections. Follow-up indicated a good outcome. Blood and operative 
specimens grew MRSA (β-lactam resistant only; unavailable for genotyping). 
Case 3. An 11-year-old Polynesian boy presented with fever and left periorbital swelling 
within 48 hours of developing a pustule on the eyelid. He and family members had a 
history of skin infections. Initial CT scans showed indurated periorbital tissue and minor 
inflammatory phlegmon in the lateral postseptal extraconal position. After failing to improve 
with flucloxacillin and cefotaxime by day 4, lincomycin was added. Repeat imaging found 
extensive periorbital soft-tissue swelling and an orbital abscess, with no evidence of sinus 
disease. At surgery, he had signs of necrotizing fasciitis involving periorbital tissue, which 
was debrided and the orbital abscess drained. Following culture results lincomycin 
became the sole agent for the next 8 days, followed by oral clindamycin for another 3 
weeks. He also received IVIG 1 g/kg immediately after surgery. Although blood cultures 
were negative, operative samples grew an MRSA (β-lactam resistant only; genotype 
CC30-MRSA PVL+). He underwent successful surgical correction of left-sided ptosis 3 
months later. 
Case 4. A 14-day-old female child, born at term after an uneventful pregnancy and 
delivery, presented with fever and lethargy, followed by right periorbital swelling and 
purulent ocular discharge. CT scans showed multiple locules of low density fluid with 
irregular enhancing margins in the right orbit, while the ethmoid air cells were replaced 
with soft-tissue density signal. She underwent drainage of the orbital collection and the 
initial antibiotics (flucloxacillin and ceftriaxone) were changed to IV lincomycin for 21 days 
following culture results. She also received dexamethasone 0.1 mg/kg 8 hourly (weaned 
over 10 days). At the age of 6 months, her ocular examination was normal. Although blood 
cultures were sterile, operative specimens grew MRSA (β-lactam resistant only; genotype 
ST93-MRSA-IV; PVL+). 
Orbital Cellulitis Cases and Microbiology. Forty-three patients (of which 25 were males) 
aged 14 days to 17 years (median 8.3-years) were treated for orbital cellulitis between July 
2000 and June 2010. Of the 24 (56%) cases with positive cultures, 7 grew Str. milleri 
group organisms alone; 5, meticillin-susceptible S. aureus; 4, MRSA (current cases); 1 
each of H. influenzae, Str. pyogenes, Str. pneumoniae, Str. milleri and meticillin-
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susceptible S. aureus, and Str. milleri and mixed anaerobes; and 3, mixed upper airway 
commensal flora. The only positive blood cultures were in 2 patients with MRSA. 
Furthermore, although no MRSA orbital cellulitis was noted before 2009, CA-MRSA strains 
caused 4/9 (44%) cases of orbital cellulitis treated in the 18-month period, January 2009 to 
June 2010; Fisher exact test p<0.01 (compared with no MRSA in 34 cases of orbital 
cellulitis 2000-2008). 
Literature Review. All CA-MRSA ocular infection case reports and series in the literature 
that included paediatric cases (186-199) are shown in the Table 5. These prior reports 
documented MRSA from appropriate culture samples but did not report S. aureus isolate 
genotype data or information on PVL status. 
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TABLE 5: List of all CA-MRSA ocular infection case reports and series with paediatric cases. 
                  
Author Year Country Pediatric Age Nature on Infection Infection  Treatment Outcome 
      Cases     at other sites     
Current report 2011 Australia 4 2wks-13y orbital cellulitis  bacteraemia (2) VA,DA, surgery cure 
     
(+ abscess in 3) 
   Seltz et al (186) 2011 USA 1 child ≤18y orbital cellulitis NS NS NS 
Kobayashi et al (187) 2011 USA 2 2m, 4m orbital cellulitis bacteraemia (2) antibiotics, surgery (1)  cure 
     
 (+ abscess in 1) 
   Liao et al (188) 2010 USA 2 5y, 18y orbital cellulitis NS NS NS 
Rutar (189) 2009 USA 1 12d dacryocystitis,  bacteraemia, VA,  RIF cure 
     
periorbital cellulitis  lung abscess 
  Goldstein & Shelsta 
(190) 2009 USA 5 
infant - 
teen periorbital &  NS antibiotics, surgery cure 
     
orbital cellulitis 
   Bukhari et al (191) 2009 Saudi  1 3m  orbital cellulitis  brain abscess VA, surgery cure 
  
Arabia 
  
& abscess 
   Vazan & Kodsi (192) 2008 USA 1 16m  orbital cellulitis bacteraemia VA,DA, surgery cure 
Kadhiravan et al 
(193) 2008 India 1 16y  orbital cellulitis bacteraemia,  VA cure 
      
Lemierre's, septic PE 
  McKinley et al (194) 2007 USA 8 1wk-16yrs orbital cellulitis NS antibiotics +/- surgery NS 
Rogers et al (195) 2007 USA 1 13d orbital cellulitis + abscess bacteraemia DA, surgery cure 
Miller et al (196) 2006 USA 4 <1y orbital cellulitis bacteraemia (2) VA, steroids, surgery NS 
Bloomquist (197) 2006 USA 6 <16y blebitis, conjunctivitis,   NS NS NS 
     
lid abscess, dacrocystitis, 
   
     
 periorbital cellulitis 
   Kodsi (198) 2006 USA 1 9m  chronic dacryocystitis Nil probe NLD (later) cure 
Huang et al (199) 2005 Taiwan 1 6y   orbital cellulitis + abscess brain abscess VA, RIF, no surgery cure 
NS indicates not stated; VA, vancomycin; RIF, rifampin; DA, clindamycin; PE, pulmonary emboli; NLD, nasolacrimal duct.    
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Discussion 
CA-MRSA appears to have been first reported as a cause of paediatric ocular infections in 
2005 (199). Most reports originated from the US (186-190, 192, 194-198). However, there 
are few epidemiologic data for CA-MRSA eye infections. In 2 recent case-series (including 
adolescents and adults (190) and infants (196)), CA-MRSA was the most common cause 
of periorbital or orbital infection. In a Texan paediatric series (194), 8/11 (73%) S. aureus 
isolates from 38 cases of orbital cellulitis were MRSA, however, in a Colorado series (186) 
only 1/8 S. aureus isolates were MRSA. Our data from a single institution are consistent 
with the recent emergence of CA-MRSA as a significant cause of orbital cellulitis. 
 
In Australia, cavernous sinus thrombosis and meningitis in an adult (CA-MRSA; ST93; 
PVL+) (76), and a rare case of Pott’s puffy tumour with bilateral orbital abscesses in a 
preterm neonate caused by (hospital-associated) non-multidrug resistant MRSA (genotype 
not determined) (200) have both been reported from Brisbane. 
Many of the reported CA-MRSA infections are described as severe with periorbital 
infection spreading through tissue planes, causing necrosis, and requiring repeated 
surgical intervention (190). Case 3 in our series had evidence of such tissue effects. 
Systemic complications such as bacteraemia, pneumonia, brain, and lung abscesses are 
also reported (187, 189, 191-193, 195, 196, 199), all of which can be features of severe 
PVL+ CA-MRSA infections. Two of our 4 cases had bacteraemia, but no complications at 
other sites were observed. Vancomycin remains the recommended treatment for serious 
CA-MRSA infections (69), although lincosamides, for example, lincomycin and clindamycin 
(for susceptible isolates), or linezolid can be used if the patient is stable and clears the 
bacteraemia rapidly. Combination therapy of vancomycin with agents such as clindamycin, 
rifampicin, or linezolid that suppress PVL synthesis in vitro has been supported (82-84) but 
not universally recommended (69) and is best individualized in those with serious disease. 
Surgical drainage is often required for intraorbital collections, which if untreated can lead to 
intracranial spread of infection, thromboses, and blindness. Despite the potentially serious 
adverse outcomes from CA-MRSA orbital infections, most studies (187, 189-193, 195, 
198, 199) report a good response to treatment. 
Given the documented increase in CA-MRSA infections globally and recent reports 
(including this one in Australian children) of it causing serious ocular disease, it is apparent 
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that CA-MRSA is emerging as an important ocular pathogen. In regions where CA-MRSA 
is prevalent, this fact should be taken into account during the initial empiric treatment for 
severe ocular infections. 
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Part B 
S. aureus bacteraemia in children: 
 
 
Paediatric Staphylococcus aureus bacteraemia: a systematic review 
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Abstract 
 
 
Background 
Staphylococcus aureus bacteraemia (SAB) is a well recognised and significant infection in 
adult health care literature but has received less attention in children.  
 
Objective 
To examine available information on the epidemiological and clinical features of SAB in 
children including incidence, predisposing conditions, causes, outcomes, meticillin 
resistance and changes in features over time. 
 
Data Sources 
Three databases, Medline (1948-2015), Embase (1966) and the Cochrane Library (1996-
2015) were searched for published case series of SAB in children aged 0–20 years.  
 
Study Selection & Synthesis 
Twenty four eligible studies were identified. Eighteen were retrospective, thirteen had <100 
cases, and 18 were from industrialised countries. Qualitative review and comparison of 
studies only was performed. 
 
Results 
Wide variations existed in patient characteristics, origin or sites of infection, and outcomes 
in reported case series of children with SAB. Health care acquisition or association (where 
included) was implicated in 10–86% of episodes, while infective endocarditis complicated 
a median 2.5% of cases. Recent increases in SAB incidence and meticillin-resistance 
were observed. In contrast, mortality declined over three decades from 19.6% to 2.5% in 
one study, but was higher in developing countries and in those with co-morbidities. 
 
Conclusion  
 Although SAB is an important and increasing problem, there is limited evidence on which 
to base the assessment and treatment of SAB in children.  Large, well-designed 
prospective studies on paediatric SAB are required to improve management and facilitate 
its prevention. 
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Introduction 
At any one time Staphylococcus aureus colonises 20–30% of the general population, with 
higher rates seen in children (201).   Such colonisation plays a role in subsequent infection 
and worldwide, S. aureus is an important cause of community and health-care associated 
infections in all age groups ranging from minor episodes of pyoderma to severe deep-
seated infections and life threatening sepsis (202). S. aureus bacteraemia (SAB) is part of 
this spectrum and may occur: (i) with focal or multi-focal infections, (ii) when no source is 
found and (iii) as a nosocomial bloodstream infection from a medical device, such as an 
infected vascular catheter (203). 
 
S. aureus is also an important cause of bacteraemia in children. Following the introduction 
of universal pneumococcal conjugate vaccination, a retrospective case series from a large 
Northern California health care provider found that 16% of community-onset bacteraemia 
in children aged 3–36  months was due to S. aureus (204) Similarly, a meta-analysis of 22 
studies from Africa recorded S. aureus present in 12% of community-associated 
bacteraemia episodes (205). In the hospital setting, a national network of 36 paediatric 
intensive care units from the US reported that S. aureus was responsible for around 9% of 
catheter-related blood stream infections (206). 
 
While many factors are involved, infants and young children may have higher rates of 
infection than young adults (207). There are recent reports of increased rates of paediatric 
staphylococcal infections, including bacteraemia in industrialised countries (111, 113, 
208). In some cases this relates to the recent rapid expansion and global spread of 
community-associated meticillin-resistant S. aureus (CA-MRSA) clones (7, 111). The 
features of SAB have been studied in adults extensively, there are management guidelines 
available (209, 210), and nosocomial SAB is viewed as an important quality indicator for 
health-care systems (211). In marked contrast, few data exist for SAB in children.  To help 
address this knowledge gap, and to inform future evidence-based clinical management 
decisions and public health prevention strategies, we undertook a systematic review of 
published case series of paediatric SAB, focussing upon its epidemiology, causes, rates of 
meticillin-resistance and outcomes including variations in these features over time and 
setting.  
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Methods 
Search Strategy 
A literature search on MEDLINE (Ebsco) (from 1948), EMBASE (from 1966) and the 
Cochrane Library (from 1996) until October 2015 used the following key words: 
Staphylococcus aureus or Staphylococcal infections; and bacteraemia or septicaemia or 
sepsis or bloodstream or blood culture (see Appendix pg 87). Article titles and abstracts 
were screened in EndNote 16 (Thompson Reuters), duplicates removed and articles of 
potential interest identified. Review of articles in all languages (with English title/abstract) 
was attempted. The references of included studies were also examined.  
 
Study Selection 
Published series on SAB confined to children aged 0–20 years were included.  Series 
restricted to neonates or infants, those selected by antibiotic sensitivity (MRSA/MSSA), 
disease severity (e.g. disseminated infection), particular hospital treatment setting or 
specific patient group (e.g. neonatal unit, intensive care unit, oncology service, HIV 
infected), diagnosis or nosocomial origin only were excluded.  Articles had to include 
information on sites of infection and outcomes such as mortality.  
 
Data Extraction 
For each included article, publication year, study site and years, study design 
(retrospective or prospective), inclusion criteria, numbers, age (median, mean and range), 
sex, presence of any underlying medical conditions, neonates, hospital-acquired or 
associated of bacteraemia, site(s) of infection, meticillin-resistance, and mortality were 
extracted into spreadsheets.  Where mentioned, treatment duration, change in proportion 
of meticillin-resistance and SAB incidence data were also recorded. 
 
Data Synthesis & Analysis 
Only qualitative and descriptive analysis and comparisons of selected studies was 
performed. 
 
This study has been prepared using the  PRISMA format and methodology 
recommendations (212). 
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Results 
Literature Search 
The search retrieved 5951 article references of which 250 were selected and obtained for 
further review (Figure 9).  French, Spanish, Japanese and Chinese articles were able to be 
reviewed, but not articles in Russian. Twenty four paediatric SAB series were finally 
included (Table 6) (31, 208, 213-234). In view of the relatively limited data, publications 
were not evaluated by quality criteria. Similarly, no pooling of data was attempted because 
of statistical heterogeneity (e.g. I2 = 85% for mortality proportions across studies).    
 
Study Setting and Patient Inclusion Criteria 
The 24 articles were published between 1976 and 2015 (eight since 2010) with cases 
accrued between 1971 and 2011. Six studies enrolled patients prospectively, one was part 
prospective, part retrospective and the remaining had a retrospective design. Most studies 
came from developed countries (North America – eight, Europe – seven, Australia and 
New Zealand one each), with three from South America (Argentina), and four from Africa. 
Eighteen involved a single institution, one included six tertiary hospitals in two separate 
regions of the same country (NZ), while two were national (Denmark, Iceland). A single 
positive blood culture was the sole entry criterion in 18 studies with the rest requiring in 
addition a compatible clinical illness or two positive blood cultures.   
 
Patient Demographic and Other Characteristics  
The studies included around 5341 analysed patients of whom 2648 (50%) were in the 
Danish SAB registry report (208). The studies were otherwise small with 13 reporting <100 
cases. Males predominated in 20 of 22 individual studies recording gender (range 47–
75%; median proportion of 58%). In contrast, median or mean ages in studies varied 
widely from one month to seven years.  
 
The median (range) proportion of neonates (Table 6), was 13% (7.4%–61%) in 13 studies 
where infants <1 month of age were included and the proportion was identifiable. Two 
further studies included premature infants (not further defined) who made up 18% (222) 
and 31% (227) of the series and four studies did not include infants <1 month of age.  The 
median (range) proportion of children with a chronic underlying medical condition 
(identifiable in 19 studies) was 52% (20%–84%). In two studies from South Africa, the HIV 
positive rate was used – approximately 20% (216) and 42% (known to be positive; with 
approximately 20% status not known) (218). 
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Hospital versus Community Association of Infection 
Studies reported hospital-acquired (generally identified as occurring >48 hours after 
admission) bacteraemia, with some also indicating a ‘healthcare associated’ category. 
These categories made up a widely ranging proportion of SAB cases, with median of 
individual study proportions 43%; range 10-86%, in the 20 studies that included and 
indicated nosocomial infections (1996–2000 data for 1-20 year olds (44-46%) used for 
Danish study (208)).  Of the three studies that described community onset bacteraemia 
cases only (218, 220, 231), one also noted that nosocomial SAB made up 71% of all 
paediatric SAB cases seen in the institution over the study time frame (220). Of relevance 
to hospital association of infections was the varying proportion of SAB associated with 
central venous catheters (see paragraph ‘Infection Site’ pg 80) and proportion of children 
identified as having chronic medical conditions (paragraph above).  
 
SAB Incidence 
Five studies reported varied SAB incidence in patients using hospitalisation numbers as 
the denominator. These rates were 32.8/10,000 admissions (216), 37/10,000 
hospitalisations (221), 4–8.5/10,000 admissions yearly (224), 11.3/10,000 admissions 
(229), and positive S. aureus blood cultures in 29/10,000 admissions (with 77% of these 
deemed to be genuine bacteraemia) (233). 
 
Population-based incidence information on SAB was available from six studies. Over the 
study period (1971–2000) SAB incidence rates in Danish children aged 0–20 years 
increased from 4.6/100,000 (1971–1975) to 8.4/100,000 (1996–2000) age-adjusted 
population (208).  . Highest rates were observed in infants <1 year of age, which increased 
from 36.7/100,000 in 1971–1975 to 55.6/100,000 in 1996–2000. In Iceland the rate was 
10.9/100000 (58.8 in <1 year olds) with a 36% decrease from 13.1/100,000 (1995-2003) to 
8.4/100,000 (2004-2011). (213). In the NZ study, the incidence in children aged <16 years 
was 16.9/100,000; with highest rates observed in Maori and Pacific Island infants <1 year 
of age at 63 and 105/100,000 respectively (31). Other incidence rates were an estimated 
20.8/100,000 in southern Madrid (214), 26/100,000 in Soweto, Johannesburg (218) and 
5.9/100,000 in Calgary, Canada (219). 
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Infection Site 
Infection sources and site(s) were variously categorised making comparisons between 
studies difficult. The terms ‘sepsis’, ‘no focus’ or ‘unknown focus’ were used in 18 studies 
where as a source of infection they accounted for 5–83% of cases. Other important sites 
involved skin and soft tissues in 7%–94% of cases and bones and joints in 8–56% of 
children with SAB. Central venous catheters (CVC) and other intravenous (IV) lines were 
also important sites or sources of infection (reported as the source or present at the time of 
diagnoses) with marked variation between studies (see Table 6). 
 
Infective Endocarditis 
Infective endocarditis was diagnosed in 0–12% (median 2.7%) of SAB cases.  For the 30 
cases of infective endocarditis/endovascular infection where the information was specified, 
22 had a risk factor such as congenital heart disease or a CVC present. Reported use of 
echocardiography varied widely.  In six series, echocardiography appeared to be used 
fairly extensively (215, 217, 222, 223, 227, 232). For example, in the study from 
Cambridge, UK (215), 80% of children with SAB had echocardiography following 
implementation of Infectious Diseases consultation for SAB (there was one case in the 
total 63 patients of IE).  In the remaining studies this was either not stated or confined to a 
minority of children, without generally identifying the indications for this investigation. 
 
Meticillin Resistance  
Meticillin-resistance was identified in 0–56% (median 14%) of episodes in the series. Five 
studies from the Unites States since 2005 reported MRSA in 6–33% of children with SAB. 
In four studies there was evidence of MRSA proportions increasing over time,(220, 221, 
223, 224) for example from 9% to 24% between 2001 and 2006 (221) (California, USA) 
and from 3% (1993–2004) to 47% (2004–2007) in a community onset SAB series from 
Buenos Aries, Argentina (220). 
 
Treatment Duration 
Ten articles reported on duration of treatment. This varied with study and the proportions 
of cases associated with deep-seated infections, such as septic arthritis, osteomyelitis and 
infective endocarditis where longer treatment courses are recommended.  Reported 
treatment median (and range) durations in the different studies included: 10 (7–42) days 
(224);  10 (4–42) days for SSTIs and 9 (1 - patient deceased, to 28) days for neonates 
(225); 9 (1–23) days (231); and 10.1 (1–43); and 16.6 (1–45) days (in different periods of  
81 
 
 
 
the study; 1993–2004 and 2004–2007 respectively) (220);  and 20 (10–44) days for all 
cases and 34 (29–44) for endocarditis (232). When specified in three studies, the median 
(range) duration of IV antibiotic treatment for all SAB-associated infections was 13.5 days 
(7-21) and 18 (15-29) (pre and post implementation of ID consultation for SAB) (215); 11.0 
(0–89) (31) and 12.7 (range not stated) days (234). IV catheter infections were treated 
intravenously for 10 (1–28) days and osteoarticular infections IV for 17 (3–89) days with 
total duration including oral antibiotics 46 (21–105) days (31).  
 
Mortality 
All cause mortality varied from 0%–26% (median 7.5%; 1996–2000 figure used for Danish 
Registry study). Highest mortality rates were in a 1976 study (26%) (234), with deaths 
resulting mainly from malignancy,  and in studies from Kenya (25%) (228) and Argentina 
(20%) (231). However, mortality was lower (11%) in the recent Argentinean study from the 
same institution (220). Similarly, the Danish Registry study documented a fall in mortality 
from 19.6% to 2.5% over the period 1971–2000. 
 
Mortality was associated with co-morbidities (213, 223, 224, 227, 234), and was higher in 
some developing country studies (228). One study (221) found 4% mortality for SAB from 
meticillin-susceptible S. aureus (MSSA) strains and 10% if caused by  MRSA, but the 
difference was not statistically significant. Similarly, in another study meticillin-resistance 
was a risk factor for death in simple multivariate analysis, but the risk became non-
significant as more factors were added to the model (233). However, MRSA was a risk 
factor for death in multivariate analysis in the study from Cape Town (OR 3.76; 95% CI 
1.12-12.67) (216). The Danish Registry study (208) had too few MRSA deaths for further 
analysis but noted mortality of 3.9% for hospital-associated and 0.6% in community-
associated infections (1996–2000 data). In this study, multivariate analysis showed that 
pulmonary infection (for <1yr and 11–20yr age groups), infective endocarditis (age 0–
10yrs), underlying chronic medical conditions (in those aged >1yr) and hospital-acquired 
infections (age 11–20yrs) were associated with increased mortality. In other studies, 
infective endocarditis (227), no identified source for infection and younger age (228) were 
factors associated with an increased risk of death from SAB.  
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Changes Over Time 
The studies had reported on SAB cases occurring between 1971 and 2011.  Two studies 
reported changes in the population incidence of paediatric SAB over their timeframe – an 
83% increase between 1971-1975 and 1996-2000 in Denmark (208) while in Iceland there 
was a 36% decrease from 1995-2003 to 2004-2011.  Reductions in mortality were also 
reported in studies from Denmark (19.6% to 2.5% between 1971-2000) (208)  and from a 
single Argentinean hospital; 20% (1900-1994) to 11% (1993-2007) (220, 231). Higher (all-
cause) mortality of 26% was also reported in the oldest study (1971-1973) (234). The four 
studies that noted an increase in meticillin resistance (220, 221, 223, 224) reported this as 
occurring in the early to middle part of the decade to 2010 compared to data from the 
1990s or early 2000s at the reporting hospitals.  
 
Resource Limited Settings 
Four studies from Africa (South Africa and Kenya) were identified with cases occurring in 
the 1990s and 2000s (216, 218, 228, 232).  Mortality was generally higher in these studies 
(8%-25%) and highest in the earlier (1990s) periods.  South African studies from the 2000s 
(216, 218) reported a high rate of HIV infection in cases.  These studies also reported little 
or no use or association of SAB with CVCs.   
 
Multiple SAB Episodes 
Eight of the paediatric SAB series reported more bacteraemia episodes than patients (213, 
215, 216, 219, 221, 223, 224, 229). These affected <1% (219) to 5.6% and 6.6% (221, 
223) of patients. Within 90 days of the initial episode; 5.5% had what was reported as 
relapse (213) or recurrence in 4.7% (215). In another study, around 4.6% had further 
episodes >30 days after the first SAB (216). 
 
S. aureus as a Contaminant of Blood Cultures  
Ten studies (two prospective) that assessed all positive S. aureus blood cultures classified 
a proportion of single positive cultures as contaminants based on lack of clinical evidence 
for infection and usually recovery without treatment. The proportion ranged from 2% to 
34% with higher values (29% and 34%) from two earlier studies (232, 234). Outcomes of 
these patients were not presented in detail, but they appeared to have recovered without 
anti-staphylococcal antibiotic treatment.  
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Discussion 
A relatively small number of paediatric SAB series were identified. Most were 
retrospective, many were conducted in industrialised countries, and most in the last 15 
years.  The majority were single institution studies, leading to variations in predisposing 
factors, sites of infection and outcomes.  Many aspects of SAB are likely influenced by 
additional host factors, such as associated co-morbidities, treatment-related immune-
suppression and the presence of intravascular devices.  Broadly, these could be 
conceptualised as differences between community-onset and health-care associated SAB, 
including their relative proportions in a setting. 
.  
The incidence of paediatric SAB varied widely between hospitals (223, 224, 229) and 
regions (31, 208, 213, 218, 219). Regional variation in paediatric SAB incidence is also 
evident in other reports that were not included as a paediatric SAB series in the systematic 
review (207, 235-241). Higher annual incidence rates are reported in infants <1 year of 
age (24–178/100,000) (208, 213, 218, 219, 235-238), in infants from developing countries 
(89–178/100,000) (236, 238), and amongst particular ethnic groups (such as NZ’s Pacific 
Island infants; 105/100,000) within developed countries (31).  Data from the Danish 
national registry (208) and a large US paediatric hospital network information system (111) 
indicate evidence for recent increases in SAB incidence in some regions. Possible reasons 
include increased rates of SAB in neonates and young infants (235, 240) resulting from 
extended neonatal care, increased numbers of immunocompromised children and use of 
invasive medical devices all resulting in more nosocomial infections, and dissemination of 
new community  S. aureus clones, such as USA300 (111). Improved bacteraemia 
ascertainment by a greater frequency of blood culture collections (242) and changes in 
blood culture methodologies (243)  may also play a role in increased SAB detection rates. 
A reduced number of blood culture collections as well as increased hospital infection 
control measures was mentioned in the Iceland study which a saw a reduction in SAB 
incidence over the study time period (213). 
 
Of interest is that on occasions some authors regarded S. aureus as a blood culture 
contaminant. This contrasts with the experience in adults where a recent review found only 
27/1809 (1.5%) episodes of SAB were due to contamination (210). However, there was 
limited information on the episodes where S. aureus was regarded as a contaminant. In 
view of its potential seriousness, careful consideration of the significance of blood cultures 
positive for S. aureus would be appropriate. 
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Paediatric SAB accompanying SSTIs and osteoarticular infection are well recognised in 
community-onset S. aureus infections. However, this review also found intravascular 
catheters, including CVCs, (hence hospital-acquired / health care associated infections) 
appeared to play an important role in paediatric S. aureus bacteraemia (215, 221, 223, 
224, 227). Clearly this indicates that SAB is also an important nosocomial infection where 
there is still considerable scope for prevention (244). 
 
Whilst in adults echocardiography is recommended for all patients with SAB (209), 
paediatric practice is highly variable.  In the series identified in this review, the proportion 
of SAB secondary to infective endocarditis was ≤5% in most studies.  Although rates of 6–
12% were reported in four studies (224, 226, 227, 232), these involved just 131 patients. 
Moreover, the case series (227) with the highest infective endocarditis rate (5/51) was 
unusual as more than one-third of cases had underlying heart disease and originated from 
a tertiary paediatric centre with a major cardiac surgery programme. It seems reasonable 
to conclude that on available evidence, children with SAB do not require routine 
echocardiographic assessment for endocarditis. However, such assessment may be 
needed in children with risk factors such as underlying congenital or rheumatic heart 
disease or when blood cultures remain positive >1 day, suggesting a possible deep-seated 
infection (217, 222, 245).   
 
Proportions of SAB from MRSA vary widely with region and over time, with increases most 
marked in recent years (221, 223, 224, 246). Differences between countries were 
highlighted in a recent report (247), which estimated CA-MRSA bacteraemia rates in 
2006–2007 for infants <1 year and children aged 2–17  years at 4.8 and 1.1/100,000 in the 
US and 0.9 and 0.9/100,000 in England respectively. Rates of hospital-associated (HA)-
MRSA bacteraemia in the same age groups were 7.2 and 0.2/100,000 (US), and 3.7 and 
0.2/100,000 (England) respectively. Variations in MRSA bacteraemia between hospitals 
within the same country also occur. An Australian survey in 2006 of all paediatric hospital 
S. aureus blood isolates showed that meticillin-resistance ranged from 0–30% (albeit with 
small numbers in some hospitals) with 11.7% MRSA prevalence overall (248).   
The SAB series from the US in the current review are likely to only partly reflect recent 
changes in CA-MRSA epidemiology. There have been rapid increases in CA-MRSA 
infection rates during the first decade of this century (111), while the identified SAB series 
contain data only until the first half of the decade to 2010 (221-224). In recent reports from 
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two individual US paediatric hospitals, the proportion of invasive community-onset S. 
aureus infections due to MRSA strains were 37% (22) and 60% (24) respectively. 
Furthermore, in the recent Argentinean paediatric community-onset SAB series (220), the 
proportion of meticillin-resistance rose from 3% (1993–2004) to 47% (2004–2007) which 
occurred in the context of emerging local CA-MRSA clones (249). Monitoring the local 
epidemiology of S. aureus antibiotic resistance is therefore important when informing 
decisions on the empiric management of SAB (69).  
 
Treatment duration for paediatric SAB varied with the underlying diagnosis but short 
(median 10 days) antibiotic courses were reported as widely used. This is in contrast to 
adults, where recurrences of SAB following treatment courses <10 days are observed 
(250). While such recurrence studies were generally limited by either small numbers or 
their retrospective design, a prospective multi-centre study of consecutive adults with SAB 
reported recurrent bacteraemia in 42/448 (9.4%) patients, which on the basis of molecular 
typing was mostly (79%) due to a relapse from the original infecting strain (251). 
Endocarditis, and treatment with vancomycin for meticillin-susceptible SAB, but not 
treatment duration, were significantly associated with an increased risk of relapse.  A 
number of the included paediatric studies reported relapses of recurrences in around 5% 
of cases with apparent subsequent new infections also occurring. However, information on 
whether they were relapses / recurrences or new episodes and accompanying risk factors 
was limited - one study observed that all 21 patients with multiple SAB episodes had co-
morbidities (223) , in another, of 17 who had a second episode (> 30 days after first) six 
were MRSA bacteraemia episodes following MSSA infections suggesting a new infection 
(216). 
 
Recent mortality from paediatric SAB is low in industrialised countries and given the small 
numbers of deaths in most studies, only limited conclusions can be drawn regarding 
mortality-associated factors. Importantly, mortality appears to have fallen over the past 30 
years (208, 220, 231). Deaths are more common in those with underlying medical 
disorders and hospital-associated infections (208, 213, 223, 224, 234, 252), and in those 
living in developing countries (228). However, whether mortality is higher in SAB caused 
by MRSA rather than MSSA strains cannot be answered by the small numbers of fatal 
cases included in this review.   
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The case series we identified were mainly retrospective in nature, and often involved small 
numbers of patients (<100) from industrialised countries. In addition, case characteristics, 
infection sources and outcomes were highly heterogeneous.  Indeed, it is these variations 
in the features of paediatric SAB that are particularly striking. No series from Asia were 
included. This may reflect either no reported series from this region or non-retrieval of 
articles, perhaps from a lack of an English language abstract or other limitations in the 
search strategy. The extent to which articles from various regions (and in various 
languages) are included in the databases searched is another potential factor affecting 
study retrieval. The Argentinean group (220, 231) for example has also published data 
(253) in non-English language journals not indexed in the databases searched, with full 
text not available. 
 
This study intended to explore the broad characteristics of SAB in children (including 
changes in meticillin resistance in the context of changes in S. aureus epidemiology) and 
to draw conclusions from comparable studies. Hence the search strategy did not include in 
the analysis paediatric SAB series limited to specialised patient populations (for example 
oncology patients (254)), MRSA infections (for example in children at a Texan hospital with 
vancomycin treated MRSA bacteraemia (255)), particular infection type or health care 
setting (for example invasive CA-MRSA infections in a US ICU (256)) or studies limited to 
neonatal care where the features of SAB may be less applicable to children generally.  
Given the limited number of finally included general paediatric studies, addition of 
specialised case series may have disproportionally affected results and generalizability of 
conclusions and been practically difficult.  Review of these other studies would be worthy 
of separate analysis and could for example inform on aspects of management of SAB in 
particular diagnoses or settings and in further understanding and preventing nosocomial 
SAB. 
 
Conclusions  
Paediatric SAB is an important and increasing health problem. Patterns of infection vary 
with changes in and differences in healthcare and dissemination of particular S. aureus 
clones. Whilst varying with health care setting, nosocomial (often IV catheter-related) SAB 
is an important proportion of all SAB in children and there is considerable opportunity for 
prevention – for example by measures to reduce catheter related bloodstream infections 
(257). Increased antibiotic resistance is an increasing problem. Infective endocarditis is 
uncommon in children with SAB and routine echocardiography is not supported by current 
87 
 
 
data. Similarly, mortality is low, but may be increased in developing countries, in those with 
co-morbidities, in hospital-associated infections, and possibly with certain MRSA strains 
(258). However, infection epidemiology and characteristics, antibiotic resistance, and 
outcomes vary widely with patient population and region. Present data are limited in many 
aspects and further understanding of SAB risk factors, assessment and outcomes is 
needed to help with effectively treating and preventing these potentially serious infections 
in children. 
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APPENDIX – Search Strategy 
Ebsco MEDLINE Search Strategy (1948 to August 2011): 
(S. aureus OR Staphylococcal infections)                       
AND (Bacteremia OR Bacteremias OR Sepsis OR Septicemia OR Septicaemias OR 
Bloodstream OR Blood culture) then limited to ‘Child’ and ‘Human’                                                                       
 (MeSH and free text search for key words) 
 
EMBASE Search Strategy (1966 to August 2011): 
'staphylococcus aureus'/exp OR 'staphylococcus aureus' OR 'staphylococcal 
infections'/exp OR 'staphylococcal infections'                                                                          
                  AND ('bacteraemia'/exp OR 'bacteraemia' OR 'sepsis'/exp 
OR 'sepsis' OR 'septicemia'/exp OR 'septicemia' OR 'blood culture'/exp OR 'blood culture') 
                    AND ([embryo]/lim OR [fetus]/lim OR 
[newborn]/lim OR [infant]/lim OR [preschool]/lim OR [school]/lim OR [child]/lim OR 
[adolescent]/lim) AND [humans]/lim AND [embase]/lim  
 
Cochrane Library Search Strategy (1996 to August 2011): 
 (S. aureus OR staphylococcal infection)                       
AND (bacteraemia OR sepsis OR septicaemia OR Blood culture OR bloodstream). 
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Records retrieved  
by database searches 
 
Medline – 3308 
EMBASE – 3197 
Cochrane Reviews – 154 
 
 
Additional 
records 
identified  
248 
Non duplicate records 
screened (title ± abstract) 
5951 
Full-text articles 
sought 
257 
Records 
excluded 
5694 
Full text articles 
reviewed  
250 
 
Not reviewed in full 
text 
Not available – 1      
Russian language – 6 
Articles excluded 
(topics) 
40 - MRSA 
39 - Non-bacteraemic      
      infections included 
35 - All age/adult SAB 
38 - All cause 
paediatric   
bacteraemia 
24 - All age/adult all 
cause bacteraemia 
42 - Other  
2- Neonatal/infant 
only 
4 - Include other 
Staph sp. 
9 - Reviews 
 
 
Paediatric S aureus 
bacteraemia series 
included  
24 
FIGURE 9: Review of medical literature and selection of included paediatric SAB studies. 
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TABLE 6: Summary of included Paediatric S. aureus bacteraemia studies. 
Study Study Years Location 
Method & 
Setting
a
 
Inclusion 
Criteria 
Age Range 
Median 
[Mean] Age
b 
Asgeirsson et al 
(213) 
1995-2011 Iceland R-H(T,S) BC+ <18y 7.4y 
Barrado et al (214) 2007-2010 Madrid, Spain P-H(T) BC+ <16y 3.7y 
Saunderson et al 
(215) 
2006-2012 Cambridge, UK R/P-H(T) BC+ <16y 3.4y 
Naidoo et al (216) 2007-2011 Cape Town, S. Africa R-H(T) BC+ <13y 11.3 months 
Praino et al (217) 2008-2009 Buenos Aires, Arg. R-H(T) BC+  1.2-10.3y 4.8y 
Groome et al (218) 2005-2006 Jo'burg, S. Africa R-H(T) BC+ <13y 6-7.5 months 
Vanderkooi et al 
(219) 
2000-2006 Calgary,  Canada P-Health Region BC+ ≤18y 6.6y 
Paganini et al (220) 1993–2007 Buenos Aries, Arg. R- H(T) 2 BC or 1 + signs 1m–18y  4.8y ('04–'07) 
Burke et al (221) 2001–2006 Palo Alto, CA,USA R- H(T) BC+, signs & treatment <18y 1y (approx) 
Ross et al (222) 1992–2006 Cleveland  OH, USA R- H(T) BC+ 0–21·6y 1.9y 
Bendig et al (223) 1993–2006 Orange, CA, USA R- H(T) BC+ 0–18y 2.5y 
Hakim et al (224) 2000–2004 Buffalo,  NY, USA R- H(T) ICD 9 SAB
i
 code + BC+ 1wk–16.7y 1m 
Frederiksen et al 
(208) 
1971–2000 Denmark R- National Reported cases 0–20y - 
   
Registry 
 
[<1y
 
   
 
     
[1–10y
 
  
 
          [11–20y
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Contam 
BC 
Included 
Cases 
Male 
(%) 
Neonates 
Chronic 
Medical 
Conditions 
Health 
Care 
Acq or 
Assoc 
MRSA
c
 
Sepsis, 
Unknown            
or No 
Focus 
Origin or Involved Site of Infection 
Mortality 
(All 
Deaths) 
SSTI 
d
/ 
Surgical 
Site 
RTI
e
 OAI
f
 CVC
g
 IE
h
 
15 140 64 13% NS 49% 0% 10% 7% 6% 40% 30% 0.70% 1.4% (30d) 
 - 57 75 0% ex
j 
68% 77% 0% 30% 25%  - 12% 33%  - 7% 
3 63 63 24% Majority 68% 7.60% 14% 24% 3% 24% 46% 1.60% 4.8% (30d) 
18 365 53 10% HIV - 19.8% 49% 26% 33% 17% 22% 12% 3.30% 2.4% 8.80% 
 - 56 52 NS 56% 39% 44%  - 44% 7% 19% 16% 3.50%  - 
 - 161 50 NS HIV > 42% Not inc. 39% 10%
k 
45%
k 
35%
k 
 - -  0% 9.60% 
 - 119 57 8.40% 52% 44% 0.90% 33% 15% 3% 40% NA 5%
L 
2.50% 
- 189 56 0% 47% Not inc. 14% - 44% 16% 30% NS 2.6% 11% 
3 151 52 14% 70% 88% 19% - 17%
m
 10%
m
 8%
m
 72%
n
 1.3% 13% 
- 298 58 18%
 o
 65% 39% 16% - - - ~19%  31%
 n
 2.7% 5.8% ex
j 
- 316 61 10% Majority NS
p
 6% - - - - 53%
 n
 3.4%
Q 
3.2% 
- 36 58 61% 58% 86%
 R 
33%
 R
 84%
 R
 12% - - 67%
 n R
 7%
 R
 8% 
- 2648 64 36%
S
 28% 
 
0.5% 
      
2.5%
T
 
    
7% 74% 
 
73% 12% 4% 6% 10% 0.50% ]
r
 
    
35% 44% 
 
66% 10% 1% 24% 21% 1% ] 
        42% 47%   67% 16% 4% 22% 11% 3% ] 
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Study Study Years Location 
Method & 
Setting 
Inclusion 
Criteria 
Age Range 
Median 
[Mean] Age 
Denniston 
& Riordan (225) 
1993–2003 Birmingham,   UK R- H(S)
 
 BC+ 12d–16y 2y 
          Neonates 21d 
Mantadakis et al(226) ‘3y period’ Crete,       Greece R- H(T(1)/S(1))  2 BC or 1 + signs 1m–17y 2.5y / 4.5y cancer  
Valente et al (227) 1998–2001 Durham,  NC, USA P- H(T) BC+ 1wk–16y 16wk 
Ladhani et al (228) 1996–2001 Kilifi,           Kenya R- H(S) BC+ 1d–12y 17m 
Suryati & Watson 
(229) 
1994–1998 Sydney, Australia R- H(T) BC+ <15y 
[5.7y] 
[4.6y] (nosocomial) 
Hill et al (31) 1996–1998 New Zealand cities
U 
P- H(T)  6 Hosp BC+ <16y 7y (approx) 
Peltola et al (230) 1993–1998 Turku,       Finland R- H(T) BC+ <16y 4y 
Paganini et al (231) 1990–1994 Buenos Aries, Arg. P- H(T) 2 BC or 1 + signs 1m–15y [6.5y] 
Friedland et al (232) ‘2y period’ Jo’burg,  S. Africa P- H(T) BC+ 2wk–11y 17m 
Storch  &       
Rajagopalan (233) 
1980–1983 St Louis,   MO, USA R- H(T) BC+  Paediatric  
5.1y (CA-MSSA)
V
 
1.2y (MRSA) 
David et al (234) 1971–1973 Philadelphia, USA R- H(T) BC+ 0–15y 4y (approx) 
 
NOTES:  Method & Setting
a
: P – prospective,  R – retrospective, H – hospital, T – tertiary hospital S – secondary hospital, Median / mean age
b
: mean age if 
median not stated,  
c
Meticillin-resistant S. aureus,  
d
Skin & soft tissue infection, 
e
Respiratory tract infection, 
f
Osteoarticular infection, 
g
Central venous 
catheter, 
h
Infective Endocarditis,  
i
International Classification of Diseases 9 SAB code, 
j
Excluded cases, 
k
Admission diagnosis, 
L
Endovascular infections,       
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Contam 
BC 
Included 
Cases 
Male 
(%) 
Neonates 
Chronic 
Medical 
Conditions 
Health 
Care 
Acq or 
Assoc 
MRSA
a
 
Sepsis, 
Unknown            
or No 
Focus 
Origin or Involved Site of Infection 
Mortality 
(All 
Deaths) 
SSTI 
b
/ 
Surgical 
Site 
RTI
c
 OAI
d
 CVC
e
 IE
f
 
13 51 NS NS 33% 20% 
 
20% 39% 14% 29% 6% 
n
 0% 4% 
3 30 NS 100% - 100% 14% 50% 40% 9% - 52%
 n
 0% 10% 
- 18 56 0% 28% 28% 56% 11% 11% 11% 56%  - 6% 0% 
- 51 51 31%
O
 53% 63% 31% - - - 9.8% 73% 12% 18%
X
 
- 97 47 25% NS 10% 1% 46% 94%
 Z
 5.8%
Z
 31% NS 0% 25% 
- 133 61 7.4% 84%
 R
 47%
 R
 14%
 R
 49%
 R
 18%
 R
 5.7% 11%
 R
 
19%
 R
 
0.7%
R
 0.7%
aa
 
51%
 n
 
9 125 58 11% 51% 30% 6% 5% 14% 3% 42% 22% 0% 3.2% 
4 33 67 30% 24% 35% 0% 33% 9%   45% NS 3% 6% 
- 60 70 0% 55% Not inc. 3% 17% 37%
bb
 27%
cc
 37%
cc
 NS 3% 20% 
15 36 53 NS NS 47% 31% 11% 61% 33% 28% 7% 11% 15% 
11 58 NS NS 55% 38% 28% 16% 34% 17% 31% 7% 1.7% 14% 
26 50 68 10% 54% 20% 0% 30% 66%
 Z
 20%
Z
 26%
Z
 0% 0% 26%; 6%
aa
 
 
m
Additional foci of infection, 
n
CVC present at time of SAB diagnosis
 o
Premature infants (not further defined), 
p
Not Stated, 
Q
Retrospective diagnosis of IE, 
R
Proportion of bacteraemia episodes, 
S
Infants < 1 year of age, 
T
Data for 1996–2000, 
U
NZ – Auckland & Christchurch 
V
Community-associated meticillin-sensitive 
S. aureus, 
X
1yr mortality, 
Z
Of proportion in patients with foci of infection, 
aa
SAB attributable mortality, 
bb
Primary or secondary focus, 
cc
Primary focus. 
93 
 
 
Chapter 6 
 
Discussion and conclusions 
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The trajectory of CA-MRSA in the USA has been well charted, from initial isolated case 
reports (11, 14), to increasing recognition and then appreciation of impact on 
staphylococcal infection epidemiology, hospitalisations and health economics (108, 111, 
259).   
 
Similarly, reports in Australia (6, 8, 9, 53) came early in the CA-MRSA era and have been 
followed by increasing recognition and documentation of impact on infections managed in 
the community (47, 52, 124, 178) and in hospital systems (51, 56).  The studies presented 
here seek to add to our knowledge on the rise of CA-MRSA as a cause of infection, 
particularly in childhood and the impact on and changes in staphylococcal infections in 
Australia in the same time frame, with particular focus on children in Queensland, 
Australia. 
 
How much CA-MRSA is causing infections in a particular place or treatment setting and if 
there are increases in staphylococcal infections are important questions, for addressing 
empiric and subsequent treatment and considering aetiology and broader responses.  It 
has been recognised that different CA-MRSA clones have been first described in particular 
regions of Australia with subsequent spread, but differences in frequency of clones 
causing infection in the different states of Australia remain (6, 47).  
 
The Chapter 2 (part A) analysis of nationwide cutaneous abscess admission data for the 
period 1999-2014 demonstrated, as a new finding, increasing abscess admission rates in 
Australia that are highly suggestive of a significant impact of CA-MRSA on S. aureus 
infection epidemiology. The extent of the changes in national abscess admissions were 
marked, with the number of admissions yearly more than doubling and there were more 
than 10,000 additional admissions a year at the end of the time period. The absolute 
increases in some age group admission rates were also striking, with some young adult 
age ranges experiencing admission rates close to that of infants at the end of the data 
period (Figure 1 pg 16). Cutaneous abscess have been strongly associated with CA-
MRSA / PVL+ S. aureus (10, 19). The increases have occurred in the time frame over 
which CA-MRSA went from early reports to increased recognition and have occurred in 
age groups (youth to younger adults) where CA-MRSA / PVL+ S. aureus infections have 
been particularly recognised (66). However, linked microbiology results were not available 
in this study and other reasons, e.g. co-circulation of CA-MSSA PVL+ clones could also 
play a role.  
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Evidence from Queensland paediatric admissions data between 2000-2011, presented in 
Chapter 3 supports the role of S. aureus and antibiotic resistant S. aureus in abscess 
admissions, with 46% of abscess admissions coded as S. aureus related and from the 
Chapter 4 (part A) Brisbane paediatric hospital study where 70% of children admitted with 
this diagnosis had a positive culture result for S. aureus. Increases in MRSA over the time 
period were seen in both the Queensland and paediatric hospital data. 
 
Additional support for CA-MRSA leading to increases in infections is provided in the 
Chapter 3 study by the data on common staphylococcal associated SSTI admissions in 
Queensland children, with yearly rates rising around 40% at the end of the period studied. 
In these data, admissions coded for antibiotic resistant bacteria, with CA-MRSA expected 
as the cause, rose significantly, providing more evidence for a role of CA-MRSA in these 
changes. Furthermore the Chapter 4, (part B) study, genotyping S. aureus isolates at the 
Brisbane paediatric hospital confirmed the presence of the predominant CA-MRSA clone, 
ST-93 MRSA IVa, as well as the presence of PVL+ MSSA isolates causing community 
onset SSTIs.  
 
Use of coded hospitalisation data allows assessment of trends over regions and time and 
has been used to show recent increases in staphylococcal infections / SSTI in the US 
(108, 111), UK (113) and NZ (112). It is accepted that hospitalisations will capture only a 
fraction of such infections (20) with many being managed in ambulatory care or in the 
community setting. There is also evidence for CA-MRSA being an increased cause of 
SSTI in ambulatory / community settings in Australia, e.g. in Northern Territory community 
clinics (52) a NSW ED series (51) and in surveys of community onset S. aureus infections 
(47).   
 
However, the implication from the hospitalisations data is that very significant increases in 
common staphylococcal infections – likely due at least in part to CA-MRSA – have 
occurred within the first decade of this century in Australia.  It is likely that the actual 
magnitude of infections in the community, which are more difficult to measure, is much 
greater.  The health system costs are also likely to be much greater than the costs 
estimated for the additional yearly cutaneous abscess admissions.  Modelling in the US 
has suggested a societal yearly cost of CA-MRSA in the $1.4-13.8 billion US dollar range 
(110). 
96 
 
 
 
The data analysed, from national to Queensland wide paediatric and Brisbane paediatric 
hospital level, provide some information on the time course of the dissemination of CA-
MRSA within Australian populations.  It would of course be expected that there would be 
differences in regions, for different conditions and in different groups of people; however, 
the data from Queensland children is suggestive of particular increases in CA-MRSA in / 
by the second half of the decade to 2010. This would be consistent with previous reports 
on CA-MRSA in Queensland, with the first descriptions of the Queensland clone ST93 
being from infections in 2000-2001 (41) and further  reports of severe infections in the 
early to middle part of the decade (8, 9).  Information from country wide surveys of 
community onset S. aureus isolates has also shown significant presence of CA-MRSA in 
2006 and 2012 (47, 48) and 2008 data notes the significant presence of CA-MRSA at a 
NSW tertiary children’s hospital (56).   
 
National abscess hospitalisations increased progressively through 1999-2014. Increases 
from baseline year had occurred by 2007-2008 when the data were first presented (117).  
However, increases appeared to continue with a broader age cohort showing increases 
from baseline by 2013-2014. The findings would be consistent with continued 
dissemination of CA-MRSA through the later part of the decade to 2010 and beyond. The 
suggestion is of a relatively rapid change in infection epidemiology with CA-MRSA 
becoming common within a short time frame after the initial reports.  
 
Younger age groups are also at risk for PVL + S. aureus infection including in Australian 
data (66) and the findings from the data examined are consistent with this and support the 
contention for a role of CA-MRSA in the increased infections.  The increased cutaneous 
admission rates have affected children to younger to middle aged adult age ranges, 
without increased admissions in the oldest age cohorts.  Similarly, significant increases in 
staphylococcal infections (and resistant infections) were seen in children in the 
Queensland data studied. These age related propensities may reflect host factors for 
infection such as increased likelihood of person to person contact or poor hygiene in 
affected age groups. The relative sparing of older persons is intriguing. High PVL antibody 
levels were noted in older persons and the possible role of acquired immunity in protection 
against such SSTI, as opposed to being a marker of past (possibly remote past) infection  
in that age group, while an attractive hypothesis, is yet to be further supported.  
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CA-MRSA has been particularly reported in disadvantaged communities, including urban 
populations, homeless people, IVDU and also in indigenous persons in a number of 
countries (4). In infections at the Brisbane paediatric hospital, indigenous status was a risk 
factor for CA-MRSA.  In the state-wide data, much higher rates of SSTI admissions were 
seen in indigenous children throughout the period studied and without significant increases 
in overall admission rates.  However, increases in admissions expected to be due to CA-
MRSA (by ICD-10 resistance codes) were noted though the period. Previous Australian 
reports have noted much higher SSTI hospitalisation rates in indigenous children, for 
example up to 12 times higher in young indigenous children in WA in 1990-2000 data 
(260).  Reports from NZ indicate much higher rates of skin infection in children of Maori 
and Pacific Island ancestry compared with other NZ children, with correlations with social 
disadvantage (112, 143, 154) and occurred in a setting with less CA-MRSA but significant 
PVL+ MSSA (177). The increased level of infection noted in Queensland indigenous 
children is also likely mediated by associated socio-demographic factors such as socio-
economic status, household size, crowding and population age structure.  
 
The national abscess admissions data suggests changes in recent S. aureus infection 
epidemiology in Australia; however, regional variations and factors are likely to be present.  
In Queensland paediatric SSTI admissions, rates were higher overall in regional / remote 
areas than in the urban south east corner with most of the population. In the regional data, 
admissions in indigenous children were prominent and this seemed to be part of the 
explanation for the higher rates. A recent NZ study noted geographic variation in 
staphylococcal SSTI (112) with higher rates in the north compared to south, with possible 
explanations being different population mix as well as factors relating to climate (SSTI 
occurrence has been associated with warmer and more humid conditions) (261). 
Consideration of both local and larger scale trends in S. aureus infections appear to be 
important in understanding as well as managing such infections. 
 
The studies presented have shown recent significant increases in staphylococcal (skin) 
infections in Australia due to and in the context of the described rise in CA-MRSA. The 
nature and timing of changes are consistent with what is known about infection with CA-
MRSA and PVL+ strains.  The success of CA-MRSA clones has been noted but not easily 
explained. Antibiotic selection pressure, clone virulence and fitness may play a role (262). 
Strong epidemiologic linkage with PVL and the association of PVL with pyogenic infections 
in younger persons has been noted (4, 10)  and the results from the studies performed are 
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consistent with the spread of such clones in Australia. More recent considerations of S. 
aureus pathogenisis and virulence have, however, sought to explore the role of other 
factors in addition to PVL and to approach pathogenesis more broadly (176).   CA-MRSA 
are thought to be clones formed from pathogenic MSSA acquiring mecA determinants, 
with such clones having a variety of factors for virulence (138, 263, 264).  For example in 
the Australian context, ST93 MSSA is known to have been present prior to the emergence 
of the ST93 MRSA clone (42, 46), with analysis of isolates suggesting presence in North 
Western Australia in the 1970s, with meticillin resistance being acquired in the 1990s.  CA-
MRSA appears to have successfully disseminated in populations with risk factors 
conducive to skin / staphylococcal infections and then had broader impact of S. aureus 
infection epidemiology in a society. 
 
The recent Australian and Queensland data presented, highlight the possibility of rapid 
changes in S. aureus infections, including in antibiotic susceptibility and the importance of 
monitoring and responding to such changes. ‘New’ clinical manifestations of infection may 
come to prominence in such settings, examples of which include severe necrotising 
pneumonia and deep vein thrombosis (9), and similarly, severe orbital infections due to 
CA-MRSA were noted at the Brisbane children’s hospital during the time frame of the 
staphylococcal infections examined.  Such ‘novel’ findings triggered the need to reassess 
previously accepted treatment recommendations for both empiric and subsequent 
management of infections and lead to, for example, changes to antibiotics (such as 
clindamycin) with expected activity against CA-MRSA. 
 
Apparent age related, people group and geographic differences in CA-MRSA and 
staphylococcal associated skin infections highlight the variations and complexity of S. 
aureus infections.  The review of published paediatric S. aureus bacteraemia also 
highlighted such differences in causes of infection, antibiotic susceptibility and outcomes 
which varied over time, region and health care setting.  
 
The success of CA-MRSA has been well documented in the US and other countries (4, 
259). CA-MRSA is well described in Australia and the component studies presented add to 
our understanding of the effects of CA-MRSA on staphylococcal infections in Australia. 
Controlling CA-MRSA infections seems desirable but less easy to achieve.  Strategies to 
manage and prevent infections (e.g. multiple hygiene and decolonisation measures) may 
be attempted in individuals, small communities or in low incidence settings but are 
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problematic on the larger scale (93, 95) and efforts to develop successful vaccines 
continue (141).   
 
In the US, CA-MRSA rose to prominence over different time periods by region and in age 
groups (with an earlier peak in infection in children) with CA-MRSA reaching high endemic 
levels as a cause of all S. aureus infections. Peak levels may have finally been reached 
through the first decade of the 20th century (259). Intriguingly, some North American 
reports also suggest subsequent decreases from peak levels.  A Vancouver, Canada 
report (265) suggests a peak in such bacteraemia and wound infections between the years 
2005-2007 with decreases by 2011. In a US military health system (266) community onset 
MRSA bacteraemia decreased between 2005 and 2010 and the proportion of community 
onset SSTI due to MRSA decreased from 62% (2006) to 52% (2010).  Reasons for such 
falls are difficult to fully explain, but a historical parallel is the rise, dissemination (and 
subsequent decline) of the PVL+ S. aureus phage type 80/81 noted during the 1950s and 
60s (138). 
 
The data on children at the Brisbane hospital and in Queensland suggest increases in CA-
MRSA present to the end of the period for which data was available (2010-2011), and 
national cutaneous abscess admissions rates remained high (especially in the young / 
younger adult age groups) through to 2013-2014. There appeared to be no evidence for a 
decline and it is not clear if peak levels had been reached. The reported US experience 
(259) of a CA-MRSA infection peak in children with later peak in the adult population is 
also worth considering in the Australian context.  
 
The major components of this study used routinely collected coded data on hospital 
admissions to allow the study of staphylococcal infections over periods of time and over 
wide geographic areas.  The research does make assumptions on the utility of coded data 
for such purposes, for example on accuracy, completeness and consistency in coding. 
However, the consistent findings, ability to obtain microbiology test results for the 
paediatric tertiary hospital data and correlation with other contemporary information 
available on CA-MRSA in Australia support the relevance of the studies in adding to the 
understanding of CA-MRSA. 
 
Further and subsequent changes in CA-MRSA and S. aureus infections in Australia 
warrant monitoring and consideration.  As has been shown, national data on abscess 
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hospitalisations appears to reflect the rise in CA-MRSA. One can speculate that further 
study and ongoing analysis of this data over time might be a way of monitoring CA-MRSA 
activity in Australia.  Additional coded admission information, if available on a national 
basis, on presence of S. aureus and antibiotic resistant bacteria, would provide further 
more direct evidence for the ongoing role of S. aureus and of CA-MRSA in these 
infections.  Results would need to be correlated with other sources of information on S. 
aureus infection in Australia and this could include information on the molecular 
epidemiology and characteristics of infecting S. aureus strains. On a more local scale (e.g. 
hospital or regional) monitoring changes in S. aureus susceptibility and infection 
epidemiology, which can happen quickly as has been shown, informs appropriate 
treatment and preventions efforts. To this end, developments in WGS – which appear to 
be bringing this technology to clinical laboratories with increasingly competitive costs – 
may provide, as explored in the Chapter 4 (B) study, additional tools in rapidly identifying 
and monitoring the molecular epidemiology of S. aureus clones with potential local as well 
as national application. 
 
Treatment developments noted in these studies include changes in antibiotic strategies as 
CA-MRSA became recognised more commonly.  In the serious CA-MRSA ocular 
infections series (Chapter 5A) from a Brisbane tertiary paediatric hospital, β lactam 
antibiotics were used initially in all cases (some with treatment commenced at referring 
hospitals) prior to change to vancomycin and / or a lincosamide. The recognition  of these 
cases in 2009 brought to the fore the possibility of CA-MRSA as a cause of such 
infections, as well as in the SSTIs and OAIs that were seen increasingly between 2005-
2010 and anti-MRSA treatments began to be included in treatment considerations locally 
(and subsequently in guidelines).   For example, a 2012 case series of severe S. aureus 
infections in Brisbane children noted the addition of empiric anti-MRSA treatments 
(vancomycin or clindamycin) where there was an increased risk for MRSA (e.g. past 
infection in individual or family) and the use of anti-toxin antibiotic strategies for necrotizing 
S. aureus pneumonia (84).  
 
The current guidelines of the Queensland children’s health service recommend, where risk 
factors for CA-MRSA exist, immediate empiric addition of a lincosamide to the treatment 
regimen for OAIs, periorbital cellulitis and severe cellulitis (267) and for non-neonatal 
community acquired sepsis requiring ICU admission (268). Current national guidelines, 
while still recommending β lactam antibiotics for OAIs, recommend the addition of 
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vancomycin or clindamycin (where isolates are locally susceptible)  in settings where CA-
MRSA is a concern (167).  Such guidelines highlight the need for an understanding of and 
continued monitoring of local S. aureus infection epidemiology and timely revision of 
recommendations.  These may include responding to future changes in susceptibility to 
lincosamides or even decreases in CA-MRSA infections. 
 
Optimal treatment strategies for S. aureus infections warrant further consideration.  While 
drainage of cutaneous abscesses may be successful, severe invasive infections such as 
necrotizing pneumonia or disseminated / multifocal infections remain challenging to treat 
and further evidence, in addition to in vitro and case series data, including on the role of 
combination and anti-toxin antimicrobials and adjunctive treatments is required to guide 
therapy. Settings where CA-MRSA / PVL+ S. aureus infections are relatively common 
might be suitable for trials of such anti-toxin treatments, while the study of infecting isolate 
molecular characteristics and pathogenic determinants and host immune responses would 
also be required. 
 
Also of importance, is further understanding and managing the burden of SSTI (noting that 
prevention measures can be applied effectively at least on a small scale), including in 
indigenous Australians where a longstanding high burden has been noted.  The role of 
MSSA as well as CA-MRSA clones in SSTI is also an important consideration (177, 178). 
Further understanding of apparent protective factors for PVL+ infections in older persons 
may lead to new preventions strategies, such as effective vaccines. 
 
Staphylococcus aureus has proven to be a successful pathogen – even in the antibiotic 
era – and ongoing efforts to understand the pathogenesis of staphylococcal infections and 
developing novel means of prevention and treatment are still required. 
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